United States v. Loughner

672 F.3d 731, 2012 WL 688805, 2012 U.S. App. LEXIS 4489

Opinions

Opinion by Judge BYBEE; Concurrence by Judge WALLACE; Dissent by Judge BERZON.

OPINION

BYBEE, Circuit Judge:

San Francisco, California *

Jared Lee Loughner stands accused of the January 2011 murder of six people, including U.S. District Judge John Roll, and the attempted murder of thirteen others, including U.S. Representative Gabrielle Giffords. Loughner was committed to a Bureau of Prisons (“BOP”) medical facility to determine if he was competent to stand trial. After the medical staff concluded that he was not competent, the district court ordered him committed for a period of four months to determine if he could be restored to competency. While he was in custody, the facility determined that Loughner was a danger to himself or others and conducted hearings pursuant to 28 C.F.R. § 549.46(a), referred to as Harper hearings, to determine if he could be involuntarily medicated. See Washington v. Harper, 494 U.S. 210, 110 S.Ct. 1028, 108 L.Ed.2d 178 (1990). The district court denied Loughner’s emergency motion to enjoin the involuntary medication decision of June 14, 2011. The appeal from that order is before us as No. 11-10339. In the interim, Loughner was involuntarily medicated on an emergency basis pursuant to 28 C.F.R. § 549.43(b) (2010) and the district court denied Loughner’s emergency motion for a prompt post-deprivation judicial hearing. The appeal from that order is before us as No. 11-10432. The district court likewise denied Loughner’s emergency motion to enjoin the involuntary medication decision of September 15, 2011. Subsequently, the district court ordered Loughner’s commitment to be extended by an additional four months to render him competent to stand trial. See 18 U.S.C. § 4241(d). The appeal from the Septem ber 15 involuntary medication and extension of commitment orders is before us as No. 11-10504. We affirm both orders at issue in appeal No. 11-10504. We dismiss appeals No. 11-10339 and No. 11-10432 as moot.

I. BACKGROUND AND PROCEEDINGS

On March 3, 2011, a federal grand jury indicted Jared Lee Loughner for multiple criminal offenses arising from a January 8, 2011, shooting incident in Tucson, Arizona, in which six people were killed and thirteen people were injured. The charges included the attempted assassination of Congresswoman Gabrielle D. Giffords, the murder of Federal Judge John M. Roll, the murder and attempted murder of other federal employees, injuring and causing death to participants at a federally provided activity, and several related weapons offenses.

At a detention hearing on January 10, 2011, the district court determined that Loughner was a danger to the community and should be federally detained pending trial. Magistrate Judge Lawrence O. Anderson found that there was no condition or combination of conditions that would reasonably assure the safety of the community, and ordered Loughner committed to the custody of the Attorney General for confinement in a corrections facility-

On March 9, 2011, the district court granted the government’s motion for a competency examination to be conducted at the U.S. Medical Center for Federal Prisoners in Springfield, Missouri (“FMC-Springfield”), by BOP medical personnel, pursuant to 18 U.S.C. § 4247. BOP psychologist Dr. Christina Pietz and court-appointed psychiatrist Dr. Matthew Carroll determined that Loughner was not, at that time, competent to stand trial and diagnosed him with schizophrenia. The district court agreed, and on May 25, 2011, ordered Loughner committed for a four-month period of hospitalization at FMC-Springfield to determine whether he could be restored to competency, pursuant to 18 U.S.C. § 4241(d)(1).

A. Involuntary Medication

After he was returned to FMC-Springfield, Dr. Pietz asked Loughner, “on a daily basis,” if he was willing to take psychotropic medication voluntarily, but Loughner consistently declined to engage in such treatment.

1. Harper I

On June 14, FMC-Springfield staff conducted an administrative hearing, pursuant to the procedures outlined in 28 C.F.R. § 549.43¹ and Harper, 494 U.S. 210, 110 S.Ct. 1028, to determine whether Loughner should be forcibly medicated on dangerousness grounds (“Harper I hearing”). Dr. Carlos Tomelleri, an independent psychiatrist not involved in Loughner’s diagnosis or treatment, presided over the Harper I hearing, and Dr. Pietz and Dr. Robert Sarrazin, Loughner’s treating psychiatrist, also participated. John Getchell, a licensed clinical social worker (“LCSW”), was appointed by FMC-Springfield to serve as Loughner’s staff representative in the administrative hearing process. According to Getchell, he met with Loughner the day before the hearing to explain his (Getchell’s) role in the proceeding, the purpose of the hearing, Loughner’s rights, and to answer any questions Loughner may have about the process. In a written statement, Getchell stated that he informed Loughner of his right to have witnesses present at the hearing, but that Loughner did not wish to have any witnesses present. Before the hearing, Getchell again asked if Loughner wanted any witnesses and Loughner responded, “Just my attorney.” Getchell then notified Dr. Pietz and Dr. Tomelleri of Loughner’s “request to have an attorney present for the proceeding.”

The Harper I hearing took place in Loughner’s cell. At the outset, Loughner said “You have to read me the Bill of Rights or I won’t talk to you” and “I’m not an American citizen.” After Dr. Tomelleri explained that that was not part of the hearing procedure, Loughner barricaded himself behind his bed and refused to participate in the hearing, even though he was encouraged to do so by Dr. Pietz, Dr. Sarrazin, and Mr. Getchell. When he finally spoke, Loughner stated he would “plead the fifth,” he denied that he had a mental illness, and he responded “No” when asked if he would consider taking medication that would improve his condition. There is no record of Getchell making any statements or inquiries on Loughner’s behalf.

In the Involuntary Medication Report, Dr. Tomelleri authorized involuntary medication after finding that Loughner’s mental disease made him a danger to others. In the Justification section of the report, Dr. Tomelleri explained that Loughner had become enraged while being interviewed and yelled obscenities; had thrown objects, including plastic chairs and toilet paper; had spat on his attorney, lunged at her, and had to be restrained by staff; and his behavior had been characterized by indications that he was experiencing auditory hallucinations, including inappropriate laughter, poor eye contact, yelling “No!” repeatedly, and covering his ears.

Noting that Loughner had been diagnosed with schizophrenia, Dr. Tomelleri explained in the report that “[treatment with psychotropic medication is universally accepted as the choice for conditions such as Mr. Loughner’s.” Dr. Tomelleri rejected other, less intrusive measures (e.g., psychotherapy, minor tranquilizers, seclusion and restraints), because they “are not practicable,” “do not address the fundamental problem,” “have no direct effect on the core manifestations of the mental disease,” or “are merely temporary protective measures with no direct effect on mental disease.”

Loughner was advised that if involuntary medication was approved, he would have twenty-four hours to appeal the decision to the Administrator of the Mental Health Division. With the help of Getchell, Loughner submitted a written appeal that was laced with profanities. The Associate Warden of Health Services (“Associate Warden”) denied the appeal. The Associate Warden restated the evidence and found that “[wjithout psychiatric medication, you are dangerous to others by engaging in conduct, like throwing chairs, that is either intended or reasonably likely to cause physical harm to another or cause significant property damage.... At this time, medication is the best treatment for your symptoms.”

On June 21, 2011, FMC-Springfield began medicating Loughner as prescribed by Dr. Sarrazin. After becoming aware of Loughner’s involuntary medication, defense counsel filed an emergency motion in the district court on June 24, asking the court to enjoin FMC-Springfield from forcibly medicating Loughner. Loughner argued that the involuntary medication order violated his substantive due process rights by treating his mental illness without considering less intrusive methods to ameliorate his dangerousness; failed to consider how the medication would implicate his fair trial rights; and violated his procedural due process rights, as a pretrial detainee, because the hearing should have been held before a court, Loughner’s requested witness should have been called, and the specific drug and dosage that would be administered should have been set out in the hearing.

On June 29, 2011, the district court held a hearing on the motion. At the hearing, defense counsel requested an evidentiary hearing and the opportunity to present testimony from a former BOP official and a forensic psychiatrist experienced in prison administration and forced medication decisions. The district court denied both the motion and the request for an evidentiary hearing, first in an oral order from the bench, and then in a written order. In the written order, the district court explained that because Loughner was being medicated on dangerousness grounds, the substantive and procedural standards described in the Supreme Court’s decisions in “Harper, and not Riggins² or Sell,2 3 applies,” and “Harper is clear that doctors, not lawyers and judges, should answer the question whether an inmate should be involuntarily medicated to abate his dangerousness and maintain prison safety.” Order on Defs Mot. to Enjoin Medication 3, July 1, 2011. The court rejected any argument that Loughner was entitled to the higher substantive due process rights afforded in Riggins and Sell because of his status as a pretrial detainee, finding that a “dangerous individual is dangerous, whether he is a pretrial detainee or has been convicted and sentenced.” Id. at 4. The district court also rejected any argument that the staff at FMC-Springfield operates under a structural conflict of interest.

To determine the appropriate standard of review for FMC-Springfield’s decision to medicate forcibly a pretrial detainee on dangerousness grounds pursuant to Harper, the district court adopted the holding and rationale of United States v. Morgan, 193 F.3d 252, 262 (4th Cir.1999). In that decision, the Fourth Circuit found that the dangerousness determination is to be made by prison medical personnel and that the court’s involvement should be limited to a review for arbitrariness. The district court found that the procedures followed by FMC-Springfield staff at the Harper I hearing, and the findings of the presiding psychiatrist, were not arbitrary. In response to Loughner’s argument that he was denied his right to call a witness, the district court agreed “with the apparent interpretation of [the request] by [Loughner’s] staff representative who ... construed the statement as a request for legal representation at the hearing, to which he is not entitled.” Order on Def.’s Mot. to Enjoin Medication 7-8.

Loughner filed a Notice of Appeal from the district court’s order on July 1, 2011, and sought an emergency stay of forced medication from this court (No. 11-10339). A motions panel granted a temporary stay of forced medication that evening. After hearing oral arguments on the emergency motion, the motions panel issued an order on July 12, 2011, staying involuntary administration of all psychotropic medication until resolution of this appeal.

2. Emergency Medication Decision

After medication was discontinued on July 1, Loughner’s condition deteriorated significantly. On July 8, because of perceived changes in his behavior, FMC-Springfield placed Loughner on suicide watch. On July 18, FMC-Springfield doc tors determined that Loughner was a severe danger to himself and needed to be administered antipsychotic medication on an emergency basis, pursuant to 28 C.F.R. § 549.43(b).⁴

On July 22, 2011, we denied Loughner’s emergency motion seeking to enforce the July 12 involuntary medication injunction. On August 11, 2011, Loughner filed an Emergency Motion for Prompt Post-Deprivation Hearing on Forced Medication, asking the district court to enjoin the emergency medication determination. After argument on August 26, 2011, the district court denied Loughner’s motion. On August 29, 2011, Loughner filed a Notice of Appeal from that decision (No. 11-10432).

3. Harper II

On August 25, 2011, FMC-Springfield conducted a second Harper hearing (“Harper II ”), pursuant to 28 C.F.R. § 549.46(a), and Dr. Tomelleri found continued medication justified based on Loughner’s danger to himself. Although it appears that Loughner again requested Anne Chapman, one of his attorneys, to attend as a witness, she was contacted only after the hearing took place and then informed of Loughner’s request. Getchell, again acting as Loughner’s staff representative, filed an administrative appeal after Loughner declined to complete the form himself. On appeal, the Associate Warden determined that a statement from Loughner’s requested witness, Ms. Chapman, should have been obtained before, and not after, the hearing. The appeal was therefore granted, pending a new hearing.

4. Harper III

FMC-Springfield conducted a third Harper hearing (“Harper III”) on September 15, 2011, with Dr. Tomelleri again presiding. Loughner again requested Ms. Chapman as a witness. This time, Ms. Chapman was contacted and permitted to submit a written statement, which contained legal objections to the continuing involuntary medication. According to the Involuntary Medication Report, Dr. Tomelleri authorized involuntary medication based on a finding that Loughner was a danger to himself. In the Justification section of the report, Dr. Tomelleri cited the deterioration of Loughner’s condition after psychotropic medication was discontinued in July. The report indicates that many of Loughner’s most serious symptoms had receded since involuntary medication recommenced pursuant to the July emergency order, but noted that Loughner “still exhibits a tendency toward motor restlessness and pacing, ... cries frequently, and expresses intense feelings of guilt.” Dr. Tomelleri noted that Dr. Pietz had expressed concern about Loughner’s potential for suicide, and at one point Loughner had asked her, “How did you know I was going to hang myself?”

The report noted Loughner’s then-current medication regimen: 3 mg of risperidone (antipsychotic), twice a day; 300 mg of buproprion XL (antidepressant); 1 mg of benztropine (anti-cholinergic to control side effects of antipsychotics), twice a day; 1 mg of clonazepam (anxiolytic), twice a day and 2 mg at bedtime. Finding that “psychotropic medication is the treatment of choice,” Dr. Tomelleri noted that other measures did not address the fundamental problem or had no direct effect on the core manifestations of Loughner’s mental condition. The report concluded that “[discontinuation of current medications is virtually certain to result in an exacerbation of Mr. Loughner’s illness as it did when medication was discontinued in July.”

Getchell filed an appeal on Loughner’s behalf. On the appeal form, Getchell relayed that Loughner wanted to appeal because he “do[esn’t] do drugs.” The Associate Warden upheld the involuntary medication determination, finding that “Medication is the least intrusive treatment for you at this time.”

On September 23, 2011, Loughner filed an emergency motion in the district court to enjoin the involuntary medication authorized by the Harper III hearing. Loughner reiterated arguments raised in his prior involuntary medication challenges and, particular to this hearing, argued that BOP failed to find that the medication was necessary to treat his dangerousness and that his staff representative had provided inadequate assistance.

The district court denied Loughner’s motion at a hearing on September 28, 2011, and again in a September 30 written order. During the hearing, the district court noted that the involuntary medication of Loughner is “predicated on the ground of dangerousness and really has nothing to do with his competency,” and thus, those with medical training and experience “who have interaction with Mr. Loughner on a daily basis are in the best position to assess whether he’s a danger to himself and to assess his institutional needs.” Status Hr’g Tr. 295, Sept. 28, 2011. In the written order, the district court reiterated that the “decision to medicate Mr. Loughner to prevent him from harming himself or others is best made by prison doctors following administrative procedures,” and that the only issue for the court was whether the decision to medicate involuntarily was factually or procedurally deficient. Order Extending Restoration Commitment 5, Sept. 30, 2011. Finding no merit in Loughner’s challenge to the adequacy of his staff representative, the court concluded that there was “no defect in the Harper hearing conducted on September 15.” Id. at 6. The district court therefore denied the motion to enjoin Loughner’s involuntary medication, and Loughner appealed (No. 11-10504).

B. Extension of Commitment

Independent of the question whether Loughner could be involuntarily medicated because he was a danger to himself, the district court also addressed whether Loughner’s commitment at FMC-Springfield could be extended to render him competent to stand trial. See 18 U.S.C. § 4241(d)(2). On August 22 and September 7, 2011, Dr. Pietz provided the district court with reports summarizing Loughner’s hospital course at FMC-Springfield between May 27 and August 22, 2011; his current mental status and psychiatric treatment; and her opinion as to the likelihood that he could be restored to competency and the length of time it would likely take. Dr. Pietz reported that although Loughner presently remained incompetent to stand trial, she believed that “he w[ould] likely be[come] competent in the near future.” She could not predict with any degree of certainty how much additional time was needed, but stated that “[hjistorically, most defendants reach competency within 8 months of their commitment.” She then recommended a four-month extension for purposes of restoring Loughner to competency.⁵ Loughner objected to the extension of his commitment under 18 U.S.C. § 4241(d)(2).

On September 28, the district court conducted an evidentiary hearing to deter mine whether there was a substantial probability that Loughner could be restored to trial competency in a reasonable period of time. The government submitted exhibits and presented testimony from Dr. Pietz and Dr. James Ballenger, a clinical psychiatrist, to support its request for an extension of time. The defense submitted several exhibits, and cross-examined the government’s witnesses, but did not call any witnesses of its own.

At the hearing, Dr. Pietz described her observations of Loughner and discussed the differences in his behavior and abilities before medication was administered and since being medicated. Dr. Pietz testified that, in her opinion, Loughner has not experienced any significant side effects from the medication. She acknowledged, however, that the medication may be contributing to the flat, expressionless affect Loughner displayed when medication resumed. Dr. Pietz noted that Loughner is clearly improving: he no longer responds to internal stimuli, his thoughts are more rational and organized, he is better able to concentrate and hold conversations, and he is becoming more aware of how others perceive him. Overall, Dr. Pietz testified that Loughner is still depressed, but that his cognitive abilities and functioning have improved, and he is more oriented, less delusional, and less obsessed. Based on these observations, Dr. Pietz testified that she believes Loughner can be restored to competency.

Dr. Ballenger, who had not examined Loughner, testified about the rates and likelihood of restoration generally and about the history and side effects of first- and second-generation antipsychotic drugs. He testified that, in his experience, a very high percentage of people in Loughner’s condition are restored to functional competency in the clinical setting within one year of being medicated, with most of the improvement occurring between months three and twelve. He explained that restoration was indicated by the fact that such patients are no longer as delusional, are more organized in thought, can focus and concentrate, and show improvement in taking care of themselves. Dr. Ballenger testified that he had reviewed Loughner’s history and medication and, in his opinion, the current medication regimen is “highly appropriate.” Dr. Ballenger concluded that, in light of Dr. Pietz’s testimony and his own review of the records in this case, Loughner would likely be restored to trial competency within “two to six, eight more months.”

The district court held that because the burden of proof for granting an extension of commitment under § 4241(d)(2) is “substantial probability,” the government must demonstrate that Loughner is “likely” to attain competency within a reasonable time. Relying on reports submitted by Dr. Pietz before the hearing, and the testimony of Dr. Pietz and Dr. Ballenger at the hearing, the district court found that the evidence established that it is likely that Loughner will become competent to stand trial in this case and extended Loughner’s commitment under § 4241(d)(2) for four months. Loughner appealed the district court decision, and that appeal is before us now (No. 11-10504).⁶

II. JURISDICTION

Before turning to the merits, we first address our jurisdiction over Loughner’s appeals.

A. The Basis for the District Court’s Authority

In No. 11-10504, Loughner appeals the district court’s denial of his motion challenging FMC-Springfield’s September 15 decision authorizing involuntary medication.⁷ The district court’s ruling, from which Loughner appealed, was a pretrial order. As the court overseeing Loughner’s criminal prosecution, the district court has the authority to review Loughner’s motion to enjoin forcible medication. See 18 U.S.C. § 3231. The district court’s order “embodied legal conclusions related to [FMC-Springfield]’s administrative efforts to medicate [Loughner]; these efforts grew out of [Loughner]’s provisional commitment; and that provisional commitment took place pursuant to an earlier [district court] order seeking a medical determination about [Loughner]’s future competence to stand trial.” Sell, 539 U.S. at 175, 123 S.Ct. 2174 (citing Riggins, 504 U.S. 127, 112 S.Ct. 1810; Stack v. Boyle, 342 U.S. 1, 6-7, 72 S.Ct. 1, 96 L.Ed. 3 (1951)). The district court’s authority to review pretrial orders, therefore, gave it authority to review the involuntary medication of Loughner. See Riggins, 504 U.S. 127, 112 S.Ct. 1810 (reviewing trial court’s denial of defendant’s motion to suspend administration of medication during trial); United States v. Weston, 206 F.3d 9 (D.C.Cir.2000) (reviewing district court’s order upholding BOP’s decision to medicate involuntarily Weston); Morgan, 193 F.3d at 257-59 (reviewing district court’s order authorizing forcible medication pursuant to the administrative determination after the district court rejected Morgan’s motion to enjoin).

In No. 11-10504, Loughner appeals from the district court’s order extending his commitment to FMC-Springfield. The district court has the authority to extend Loughner’s commitment pursuant to 18 U.S.C. § 4241(d)(2).

B. Appellate Jurisdiction

Ordinarily, an appellate court may hear appeals only from a district court’s final decision. 28 U.S.C. § 1291. Under the collateral order doctrine, however, we may review a district court’s preliminary or interim decision when it: “(1) conclusively determines the disputed question, (2) resolves an important issue completely separate from the merits of the action, and (3) is effectively unreviewable on appeal from a final judgment.” Sell, 539 U.S. at 176, 123 S.Ct. 2174 (quoting Coopers & Lybrand v. Livesay, 437 U.S. 463, 468, 98 S.Ct. 2454, 57 L.Ed.2d 351 (1978)) (internal quotation marks omitted); see also Cohen v. Beneficial Indus. Loan Corp., 337 U.S. 541, 546, 69 S.Ct. 1221, 93 L.Ed. 1528 (1949).

The district court’s involuntary medication order falls within the collateral order doctrine.⁸ First, the order conclusively determined the disputed question— whether there is any legal basis to medicate Loughner forcibly and whether Loughner has a legal right to a judicial hearing before involuntary medication. See Sell, 539 U.S. at 176, 123 S.Ct. 2174; Morgan, 193 F.3d at 259. Second, the involuntary medication issue is important and completely separate from the merits of the action — i.e., whether Loughner is guilty or innocent of the crimes charged. See Sell, 539 U.S. at 176, 123 S.Ct. 2174; Morgan, 193 F.3d at 259. Finally, the issue is effectively unreviewable because “[b]y the time of trial [Loughner] will have undergone forced medication — the very harm that he seeks to avoid.” Sell, 539 U.S. at 176-77, 123 S.Ct. 2174. We therefore have appellate jurisdiction, under the collateral order doctrine, to review the district court’s involuntary medication order. See United States v. Ruiz-Gaxiola, 623 F.3d 684, 688 (9th Cir.2010); United States v. Grape, 549 F.3d 591, 597 (3d Cir.2008).

The district court’s commitment order is also appealable under the collateral order doctrine. See United States v. Friedman, 366 F.3d 975, 978-79 (9th Cir. 2004). First, the order “conclusively determines [Loughner]’s ‘present right to be at liberty prior to trial.’ ” Id. at 979 (quoting United States v. Gold, 790 F.2d 235, 239 (2d Cir.1986)). Second, “the issue of involuntary commitment is completely separate from the issue of whether [Loughner] committed the crime with which he is charged,” and is important because it implicates his freedom. Id. And finally, the order is effectively unreviewable because “nothing could recover for [Loughner] the time lost during his confinement.” Id. at 979 (quoting Gold, 790 F.2d at 239). Therefore, we have appellate jurisdiction to review the district court’s commitment order as well.

III. THE INVOLUNTARY MEDICATION ORDERS

Loughner raises both substantive and procedural due process challenges to his involuntary medication.

“[T]he substantive issue involves a definition of th[e] protected constitutional interest, as well as identification of the conditions under which competing state interests might outweigh it. The procedural issue concerns the minimum procedures required by the Constitution for determining that the individual’s liberty interest actually is outweighed in a particular instance.”

Harper, 494 U.S. at 220, 110 S.Ct. 1028 (alterations in original) (quoting Mills v. Rogers, 457 U.S. 291, 299, 102 S.Ct. 2442, 73 L.Ed.2d 16 (1982)). In other words, the substantive issue is “what factual circumstances must exist” before the government may involuntarily medicate Loughner; the procedural issue is whether the government’s nonjudicial process used to determine the facts was sufficient. See id.9

The determination of the appropriate constitutional standard that governs a particular inquiry is a question of law subject to de novo review. See Pierce v. Multnomah Cnty., Or., 76 F.3d 1032, 1042 (9th Cir.1996). Factual findings are reviewed for clear error. See United States v. Hinkson, 585 F.3d 1247, 1260 (9th Cir. 2009) (en banc).

We first address the contours of Loughner’s substantive due process right and then turn to his objections to the procedures afforded by 28 C.F.R. § 549.46.

A. Substantive Due Process Standard

The parties dispute the proper substantive due process standard that applies when the government seeks to medicate forcibly a pretrial detainee on the grounds that he is a danger to himself or others. The government argues that the standard announced in Harper applies; Loughner argues that the heightened standards enunciated in Riggins and Sell should apply instead. As we explain below, neither Harper nor Riggins addresses the precise question at issue here. Sell suggests an answer, and we and every court of appeals to apply this framework has assumed that the Court answered the question in Sell. Consistent with Sell’s suggestion, we hold that the standard announced in Harper applies with equal force in the context of pretrial detainees.

1. Harper, Riggins, and Sell

Washington v. Harper is the seminal involuntary medication case. 494 U.S. 210, 110 S.Ct. 1028. It involved a prisoner’s substantive and procedural due process challenge to a Washington state prison regulation authorizing the forcible medication of an inmate suffering from a mental disorder if he was “gravely disabled or pose[d] a likelihood of serious harm to himself, others, or their property.” Id. at 215, 110 S.Ct. 1028 (internal quotation marks omitted). Harper argued that, under the Due Process Clause, the State of Washington could not override his choice to refuse antipsychotic drugs absent a finding of incompetence and substituted judgment that, if he were competent, he would consent to drug treatment. Id. at 222,110 S.Ct. 1028. The Court framed the substantive issue as: “what factual circumstances must exist before the State may administer antipsychotic drugs to the prisoner against his will.” Id. at 220, 110 S.Ct. 1028.

The Court began its analysis by recognizing that inmates possess “a significant liberty interest in avoiding the unwanted administration of antipsychotic drugs under the Due Process Clause of the Fourteenth Amendment.” Id. at 221-22, 110 S.Ct. 1028. This liberty interests stems from both the drugs’ intended mind-altering effects and from their “serious, even fatal, side effects” — including acute dystonia (“severe involuntary spasm of the upper body, tongue, throat, or eyes”), akathisia “(motor restlessness, often characterized by an inability to sit still),” neuroleptic malignant syndrome “(a relatively rare condition which can lead to death from cardiac dysfunction),” and tardive dyskinesia (“a neurological disorder, irreversible in some cases, that is characterized by involuntary, uncontrollable movements of various muscles, especially around the face”).¹⁰ Id. at 229-30, 110 S.Ct. 1028.

The Court recognized, however, that an inmate’s liberty interest in avoiding unwanted medication must be “defined in the context of the inmate’s confinement.” Id. at 222, 110 S.Ct. 1028. Specifically, the Court noted “the need to reconcile our longstanding adherence to the principle that inmates retain at least some constitutional rights despite incarceration with the recognition that prison authorities are best equipped to make difficult decisions regarding prison administration.” Id. at 223-24, 110 S.Ct. 1028. To accommodate this need, the Court reiterated that “the proper standard for determining the validity of a prison regulation claimed to infringe on an inmate’s constitutional rights is to ask whether the regulation is ‘reasonably related to legitimate penological interests.’ ” Id. at 223, 110 S.Ct. 1028 (quoting Turner v. Safley, 482 U.S. 78, 89, 107 S.Ct. 2254, 96 L.Ed.2d 64 (1987)). Among the factors that determine the reasonableness of a prison regulation, the Court found three particularly relevant in the context of involuntary medication: (1) “there must be a valid, rational connection between the prison regulation and the legitimate governmental interest put forward to justify it”; (2) “a court must consider the impact accommodation of the asserted constitutional right will have on guards and other inmates, and on the allocation of prison resources generally”; and (3) “the absence of ready alternatives is evidence of the reasonableness of a prison regulation.” Id. at 224-25, 110 S.Ct. 1028 (internal quotation marks omitted).

Applying these factors to the Washington regulation, the Court concluded that the policy comported with constitutional requirements. Id. at 225, 110 S.Ct. 1028. Having deprived inmates of their liberty, the State has an obligation to provide prisoners with medical treatment consistent with both the inmates’ and the institution’s needs. Id. Thus, when the root cause of the inmate’s threat is his mental disability, “the State’s interest in decreasing the dan ger to others necessarily encompasses an interest in providing him with medical treatment for his illness.” Id. at 225-26, 110 S.Ct. 1028. Therefore, the Court determined that involuntary medication is a rational means of furthering the State’s legitimate objectives: the interest in “ensuring the safety of prison staffs and administrative personnel,” and the “duty to take reasonable measures for the prisoners’ own safety.” Id. at 225, 110 S.Ct. 1028. Finally, the Court found that the government was not required to adopt the alternative means proffered by Harper (seclusion and physical restraints) because Harper failed to demonstrate that they were “acceptable substitutes for antipsychotic drugs, in terms of either their medical effectiveness or their toll on limited prison resources.” Id. at 226-27,110 S.Ct. 1028. Accordingly, the Court held that “given the requirements of the prison environment, the Due Process Clause permits the State to treat a prison inmate who has a serious mental illness with antipsychotic drugs against his will, if the inmate is dangerous to himself or others and the treatment is in the inmate’s medical interest.” Id. at 227,110 S.Ct. 1028.

In Riggins, the Court addressed a slightly different set of interests: a criminal defendant’s challenge to his conviction on the grounds that Nevada forced him to take antipsychotic drugs during his trial. 504 U.S. at 128, 112 S.Ct. 1810. After being taken into custody, Riggins began voluntarily taking Mellaril because he was hearing voices and having trouble sleeping. See id. at 129,112 S.Ct. 1810. As preparations for trial went forward, Riggins asked the court to suspend the medication until the end of the trial, arguing that the drugs infringed upon his freedom and would deny him due process because of their effect on his demeanor and mental state during trial. See id. at 130,112 S.Ct. 1810. The court held an evidentiary hearing, in which three different doctors questioned the need for continued administration of the drugs, and then denied Riggins’s motion, giving no indication for the court’s rationale. See id. at 131-32, 112 S.Ct. 1810. Riggins continued to be medicated throughout the trial. See id. at 132, 112 S.Ct. 1810.

In reviewing the forced medication of Riggins during trial, the Supreme Court began from the premise that “[ujnder Harper, forcing antipsychotic drugs on a convicted prisoner is impermissible absent a finding of overriding justification and a determination of medical appropriateness.” Id. at 135, 112 S.Ct. 1810. Noting that the “Fourteenth Amendment affords at least as much protection to persons the State detains for trial,” the Court held that the government must show both the need for and the medical appropriateness of anti-psychotic medication. Id. (emphasis added).

The Court denied that Harper had determined the full constitutional protections of pretrial detainees. Admitting that it had “not had occasion to develop substantive standards for judging forced administration of such drugs in the trial or pretrial settings,” the Court suggested that “Nevada certainly would have satisfied due process if the prosecution had demonstrated, and the District Court had found, that treatment with antipsychotic medication was medically appropriate and, considering less intrusive alternatives, essential for the sake of Riggins’ own safety or the safety of others.” Id. The Court explained, however, that it did not have “occasion to finally prescribe such substantive standards” because the district court’s involuntary medication order made no determination of the need for the medication and no findings about reasonable alternatives. Id. at 136, 112 S.Ct. 1810. In other words, “[t]he [district] court did not acknowledge the defendant’s liberty interest in freedom from unwanted antipsychotic drugs.” Id. at 137, 112 S.Ct. 1810. The Court observed that this failure may have impaired Riggins’s constitutionally protected trial rights — including “the substance of his own testimony, his interaction with counsel, or his comprehension at trial” — and concluded that there was no basis for finding that, if Riggins had been affected by his involuntary medication, any prejudice was justified. Id. at 137-38, 112 S.Ct. 1810. The Court accordingly reversed the Nevada Supreme Court’s decision upholding Riggins’s conviction and remanded for further proceedings. Id. at 138, 112 S.Ct. 1810.

Most recently, in Sell, the Supreme Court set out the substantive standards for when the government may administer anti-psychotic drugs involuntarily to a mentally ill criminal defendant to render him competent for trial. 539 U.S. 166, 123 S.Ct. 2174. The Court adopted a more demanding standard for medicating a defendant facing trial to render that defendant competent than it required in Harper for medicating a convicted inmate to render that inmate nondangerous. The Court held that the government may forcibly medicate a mentally ill pretrial detainee for the purpose of rendering him competent to stand trial, but only if a court determines that there are important governmental trial-related interests at stake; that involuntary medication will significantly further these government interests, without causing side effects that will interfere significantly with the defendant’s fair trial rights; that the medication is necessary to further the government’s interests, taking into account less intrusive alternatives; and that the administration of the antipsychotic drugs is medically appropriate, i.e., in the defendant’s best medical interest. Id. at 180-81, 123 S.Ct. 2174; see also Witt v. Dep’t of Air Force, 527 F.3d 806, 818 (9th Cir.2008) (referring to Sell as an application of heightened scrutiny in the substantive due process context).

Sell came with an important caveat, however. “A court need not consider whether to allow forced medication for [trial competency purposes], if forced medication is warranted for a different purpose, such as the purposes set out in Harper related to the individual’s dangerousness.” Id. at 181-82, 123 S.Ct. 2174. The Court noted that there are three reasons for determining whether forced medication can be justified on alternative grounds before turning to the trial competency question: First, “the inquiry into whether medication is permissible ... to render an individual nondangerous is usually more ‘objective and manageable’ than the inquiry into whether medication is permissible to render a defendant competent.” Id. at 182, 123 S.Ct. 2174 (quoting Riggins, 504 U.S. at 140, 112 S.Ct. 1810 (Kennedy, J., concurring)). Second, “courts typically address involuntary medical treatment as a civil matter, and justify it on these alternative, Harper-type grounds.” Id. Finally, if medication is authorized on alternative grounds, “the need to consider authorization on trial competence grounds will likely disappear.” Id. at 183, 123 S.Ct. 2174. The Court explained why the purpose of the involuntary medication is relevant:

Whether a particular drug will tend to sedate a defendant, interfere with communication with counsel, prevent rapid reaction to trial developments, or diminish the ability to express emotions are matters important in determining the permissibility of medication to restore competence, but not necessarily relevant when dangerousness is primarily at issue.

Id. at 185, 123 S.Ct. 2174 (citation omitted).

2. Post-Sell Cases

The parties dispute whether the Supreme Court’s precedent answers the question in this case: what substantive due process standard must the government satisfy to medicate involuntarily a pretrial detainee on the ground that he is dangerous? The government argues that, because Loughner was being medicated for dangerousness, he may be medicated following a Harper hearing, and that Sell approved the use of “Harper-type grounds” for medicating pretrial detainees. See Sell, 539 U.S. at 182, 183, 123 S.Ct. 2174. Loughner responds that Harper addressed involuntary medication for convicted inmates, not pretrial detainees, and that Riggins requires that the government demonstrate that a pretrial detainee’s “treatment with antipsychotic medication [i]s medically appropriate and, considering less intrusive alternatives, essential for the sake of [the pretrial detaineej’s own safety or the safety of others.” Riggins, 504 U.S. at 135, 112 S.Ct. 1810.

The Court’s cases have not addressed the issue directly. The Court in Sell seemed to assume, however, that a Harper hearing would be sufficient to medicate involuntarily a pretrial detainee on dangerousness grounds. More importantly, we have made the same assumption in our prior discussions of Harper, Riggins, and Sell. Finally, post-Sell, every court of appeals to have considered the application of Harper in the pretrial detainee context has made the same assumption.

The core of Loughner’s argument comes from two statements in Riggins. First, the Court was careful to acknowledge that Harper involved a convicted prisoner: “Under Harper, forcing antipsychotic drugs on a convicted prisoner is impermissible absent a finding of overriding justification and a determination of medical appropriateness. The Fourteenth Amendment affords at least as much protection to persons the State detains for trial.” Riggins, 504 U.S. at 135, 112 S.Ct. 1810 (emphasis added). That parsing of Harper was followed with this observation:

Although we have not had occasion to develop substantive standards for judging forced administration of such drugs in the trial or pretrial settings, Nevada certainly would have satisfied due process if the prosecution had demonstrated ... that treatment with antipsychotic medication was medically appropriate and, considering less intrusive alternatives, essential for the sake of Riggins’ own safety or the safety of others.

Id. (emphasis added). Nothing in the holding of Sell fills this gap, except for the Court’s significant aside that “if forced medication is warranted for a different purpose, such as the purposes set out in Harper related to the individual’s dangerousness,” then the district court need not conduct a Sell hearing to determine whether a pretrial detainee may be medicated to render him competent to stand trial. Sell, 539 U.S. at 181-82, 123 S.Ct. 2174. When the Court later referred to “Harper-type grounds,” id. at 182, 123 S.Ct. 2174, and failed to renew its disclaimer that it had not decided the Harper question for pretrial detainees,¹¹ we and other circuits be lieved that the Court had, indeed, decided just such a question.

We first addressed the Supreme Court’s trilogy with respect to a pretrial detainee in United States v. Riverau-Guerrero, 426 F.3d 1130 (9th Cir.2005). Rivera-Guerrero was charged with illegal reentry. See id. at 1134. After he was found incompetent to stand trial, FMC-Springfield requested an order allowing it to medicate Rivera-Guerrero to restore his competence to stand trial. See id. The magistrate judge held a Sell rather than a Harper hearing and determined that Rivera-Guerrero could be medicated. See id. at 1134-35. We reversed the order on appeal on the grounds that a pretrial involuntary medication decision could not be delegated to a magistrate judge. See id. at 1136. Following the remand, FMC-Springfield began involuntarily medicating Rivera-Guerrero on an emergency basis. The district court thereafter issued an opinion adopting the recommendations of the magistrate judge — a nearly identical justification as the order we previously vacated. See id.

We began our discussion by noting that “Sell orders are disfavored. The Supreme Court clearly intends courts to explore other procedures, such as Harper hearings (which are to be employed in the case of dangerousness) before considering involuntary medication orders under Sell.” Id. at 1137 (emphasis added). Although we reversed for a procedural error in the Sell proceedings, we noted that because of Rivera-Guerrero’s involuntary medication on dangerousness grounds and confinement for more than the permissible period of time, “on remand, conducting a Sell inquiry no longer constitutes the appropriate procedure.” Id. at 1143. We instructed the district court to order FMC-Springfield to report on Rivera-Guerrero’s medical status. “If the FMC reports that Rivera-Guerrero has been rendered competent to stand trial as a result of its administration of the medication, and the district court accepts that assertion, then the district court may proceed with the criminal trial....” Id. at 1144.

In United States v. Hernandez-Vasquez, 513 F.3d 908 (9th Cir.2008), we addressed a slightly different circumstance. The government had charged Hernandez-Vasquez, like Rivera-Guerrero, with illegal reentry. See id. at 911. After the district court found Hernandez-Vasquez incompetent, he was transferred to FMC-Springfield where the government requested that he be medicated to render him competent to stand trial; in the alternative, the government asked that Hernandez-Vasquez be evaluated for dangerousness. See id. at 912. The district court conducted a Sell hearing and granted the government’s motion to medicate Hernandez-Vasquez to render him competent for trial. See id. On appeal, we noted that “a Sell inquiry is independent of the procedure that allows involuntary medication of dangerous inmates under Harper.” Id. at 913. We addressed the question of whether “the district court had an obligation to apply Harper and make a dangerousness inquiry before proceeding under Sell,” and held that “[i]f a district court does not conduct a dangerousness inquiry under Harper, it should state for the record why it is not doing so.” Id. at 914. We concluded that the district court “should take care to separate the Sell inquiry from the Harper dangerousness inquiry and not allow the inquiries to collapse into each other.” Id. at 919.

We suppose that a close reading of these cases might yield a conclusion that our statements regarding Harper are dicta. But given the extensive nature of our discussions, our lack of reservation about applying Harper to pretrial detainees, and our instructions on remand to conduct “the Harper dangerousness inquiry,” id., there is little doubt that we believe that the standards set forth in Harper apply to inmates being held by the government, whether they are awaiting trial or are serving a sentence of incarceration. See Ruiz-Gaxiola, 623 F.3d at 689 (referring to the magistrate judge ordering “the government to conduct an administrative hearing pursuant to Harper ” prior to considering an involuntary medication order under Sell for a pretrial detainee “[d]ue in part to our admonition that ‘Sell orders are disfavored’ ”).

Even if we were inclined to reweigh the factors considered by the Supreme Court in Harper in the context of a convicted prisoner, we would arrive at the conclusion that Harper applies to pretrial detainees as well. Two points are sufficient. First, we recognize that the most important factor for determining the appropriate level of scrutiny is the purpose of the involuntary medication, not the inmate’s criminal status. See United States v. Baldovinos, 434 F.3d 233, 240 (4th Cir. 2006) (“[T]he Court indicated that the determination of which principles apply— those of Harper or those of Sell — depends on the purpose for which the Government seeks to medicate the defendant.”); United States v. Brandon, 158 F.3d 947, 957 (6th Cir.1998) (“Harper’s rationale is based upon the premise that if the government’s action focuses primarily on matters of prison administration, then the action is proper if reasonably related to a legitimate penological interest, even if it implicates fundamental rights.”). If the government seeks to medicate involuntarily a pretrial detainee on trial competency grounds, that is a matter of trial administration and the heightened standard announced in Sell applies. See Sell, 539 U.S. at 183, 123 S.Ct. 2174. When dangerousness is a basis for the involuntary medication, however, as is the case with Loughner, the concerns are the orderly administration of the prison and the inmate’s medical interests. See Harper, 494 U.S. at 222-25, 110 S.Ct. 1028; Baldovinos, 434 F.3d at 240; Brandon, 158 F.3d at 957.

Second, although we recognize that in certain contexts there are important differences — differences of constitutional magnitude — between pretrial detainees and convicted detainees, see Bell v. Wolfish, 441 U.S. 520, 537, 99 S.Ct. 1861, 60 L.Ed.2d 447 (1979) (“This Court has recognized a distinction between punitive measures that may not constitutionally be imposed prior to a determination of guilt and regulatory restraints that may.”); Friedman v. Boucher, 580 F.3d 847, 853-58 (9th Cir.2009) (holding that suspicionless, warrantless searches of pretrial detainees that do not contribute to prison security are unconstitutional, and distinguishing cases upholding similar searches of convicted detainees), those differences largely disappear when the context is the administration of a prison or detention facility. As the Court stated in Bell,

[t]he fact of confinement as well as the legitimate goals and policies of the penal institution limits ... retained constitutional rights. There must be a mutual accommodation between institutional needs and objectives and the provisions of the Constitution that are of general application. This principle applies equally to pretrial detainees and convicted prisoners.

441 U.S. at 546, 99 S.Ct. 1861 (1979) (emphasis added) (citations omitted) (internal quotation marks omitted); see Bull v. City & Cnty. of San Francisco, 595 F.3d 964, 973-74 & nn. 10, 11 (9th Cir.2010) (en banc) (“We have never distinguished between pre-trial detainees and prisoners in applying the Turner test, but have identified the interests of correction facility officials responsible for pretrial detainees as being ‘penological’ in nature.”); United States v. Hearst, 563 F.2d 1331, 1345 n. 11 (9th Cir.1977) (“All legitimate intrusive prison practices have basically three purposes: the preservation of internal order and discipline, the maintenance of institutional security against escape or unauthorized entry, and the rehabilitation of the prisoners. The first two interests are implicated regardless of the status of the prisoner. The third, of course, applies only to prisoners already convicted of a crime. Accordingly, a pretrial detainee may assert his status as a shield against intrusive practices aimed solely at rehabilitation but not against practices aimed at security and discipline.” (citations omitted) (internal quotation marks omitted)). So long as Loughner is a pretrial detainee, and lawfully held, his rights are limited by the facility’s legitimate goals and policies, and his dangerousness to himself or to others may be judged by the same standard as convicted detainees. See Harper, 494 U.S. at 224, 110 S.Ct. 1028 (“We made quite clear that the standard of review we adopted in Turner applies to all circumstances in which the needs of prison administration implicate constitutional rights.”).

Finally, we observe that, post-NeZZ,¹² every court of appeals to have considered the interplay between Harper and Sell — a context that necessarily implicates pretrial detainees only — has similarly assumed that Harper is the appropriate standard for measuring whether a pretrial detainee may be involuntarily medicated because of dangerousness. See Grape, 549 F.3d at 599 (“We do not reach consideration of the four-factor Sell test unless an inmate does not qualify for forcible medication under Harper, as determined at a Harper hearing generally held within the inmate’s medical center.”); United States v. Green, 532 F.3d 538, 545 n. 5 (6th Cir.2008) (“The Sell standard applies when the forced medication is requested to restore competency to a pretrial detainee and the pretrial detainee is not a danger to himself or others. When the pretrial detainee is a potential danger to himself or others, the Harper standard is used.”); United States v. White, 431 F.3d 431, 435 (5th Cir.2005); United States v. Morrison, 415 F.3d 1180, 1186 (10th Cir.2005) (“[T]he central role of dangerousness in the Sell inquiry in this case calls out for proceeding under Harper first.”); Evans, 404 F.3d at 235 n. 3 (“The Supreme Court has outlined different tests for when the government may involuntarily medicate an individual, depending on whether the medication is for purposes of prison control or prisoner health on the one hand, see [Harper, 494 U.S. at 227, 110 S.Ct. 1028], or, on the other hand, for the purpose of prosecuting an incompetent defendant, see Sell[, 539 U.S. at 166, 123 S.Ct. 2174].”); see also Morgan, 193 F.3d at 262-63 (pre-Sell case holding that “[u]n der Harper, due process permits institutional medical personnel to forcibly treat a pretrial detainee with antipsychotic medication once they conduct the type of administrative proceeding the State of Washington employed”).

If there was any remaining doubt in our cases about the proper standard, we now hold that when the government seeks to medicate a detainee — whether pretrial or post-conviction — on the grounds that he is a danger to himself or others, the government must satisfy the standard set forth in Harper. “[T]he Due Process Clause permits the State to treat a prison inmate who has a serious mental illness with antipsychotic drugs against his will, if the inmate is dangerous to himself or others and the treatment is in the inmate’s medical interest.” Harper, 494 U.S. at 227, 110 S.Ct. 1028.

3. The Standard Applied

Having decided that Harper supplies the standard, we can easily address Loughner’s argument. Loughner argues that FMC-Springfield applied the wrong standard. Based on the assumption that Rig-gins governs here, Loughner claims that FMC-Springfield failed to demonstrate that forcibly medicating him was (1) medically appropriate and, (2) “considering less intrusive alternatives, essential for the sake of [Loughner]’s own safety or the safety of others.” Riggins, 504 U.S. at 135, 112 S.Ct. 1810.

For the reasons we have explained, the Riggins standard does not govern. We are satisfied that FMC-Springfield used the proper standard from Harper. At the Harper III hearing, Dr. Tomelleri heard the evidence from Loughner’s treating psychiatrist and psychologist and concluded that Loughner was a danger to himself, and that “[i]nvoluntary medication is ... in the patient’s best medical interest.” Dr. Tomelleri first noted that Loughner “has a well-documented history of persistent manifestations of schizophrenia” and that following discontinuation of a previous medication order, Loughner’s condition deteriorated. He further explained that “[p]sychotropic medication is the treatment of choice for conditions such as Mr. Loughner is experiencing” and that “[discontinuation of current medications is virtually certain to result in an exacerbation of Mr. Loughner’s illness as it did when medication was discontinued in July [2011].” Even though the facility was not required to demonstrate that there were no less intrusive alternatives available or that medication was “essential,” Harper, 494 U.S. at 226-27, 110 S.Ct. 1028, Dr. Tomelleri did note that other measures were inadequate because they failed to “address the fundamental problem” or “core manifestations of the mental illness.” Antipsychotics are “one of the most effective means of treating and controlling a mental illness likely to cause violent behavior”; the fact that there might be alternative means for rendering Loughner temporarily harmless (minor tranquilizers, seclusion and restraints), “do[es] not demonstrate the invalidity of the [government]^ policy” of treating the underlying mental disorder. Harper, 494 U.S. at 226, 110 S.Ct. 1028. We reject Loughner’s claim that FMC-Springfield failed to apply the appropriate substantive standard.

B. Procedural Objections

Loughner raises a number of challenges to the procedures used by FMC-Springfield to determine that he was a danger to himself or others and should be involuntarily medicated. We begin with a discussion of 28 C.F.R. § 549.46, which sets forth BOP’s “[procedures for involuntary administration of psychiatric medication.” Then we address Loughner’s general or facial challenges to these regulations. We then turn to Loughner’s as-applied challenges to the Harper III hearing held by FMC-Springfield.

1. BOP’s Regulation, 28 C.F.R. § 549.46

Like the regulation at issue in Harper, § 549.46 requires that “[w]hen an inmate is unwilling or unable to provide voluntary written informed consent for recommended psychiatric medication, the inmate will be scheduled for an administrative hearing.” 28 C.F.R. § 549.46(a). The regulation requires twenty-four-hour written notice of the hearing and a written “explanation of the reasons for the psychiatric medication proposal.” Id. § 549.46(a)(2). The inmate has the right to appear, present evidence, have a staff representative, request witnesses at the hearing, and request that his witnesses be questioned by either his staff representative or the hearing officer. If the inmate does not request a staff representative, or requests a staff representative with insufficient experience, the facility administrator must appoint a qualified staff representative. See id. § 549.46(a)(8). The hearing officer must be a psychiatrist who is not the attending psychiatrist and who is not involved in the diagnosis or treatment of the inmate, thus ensuring that there is an independent decision maker. See id. § 549.46(a)(4). The inmate’s treating psychiatrist must attend and present background information and clinical data relative to the inmate’s need for antipsychotic medication. See id. § 549.46(a)(6). The hearing officer determines

whether involuntary administration of psychiatric medication is necessary because, as a result of the mental illness or disorder, the inmate is dangerous to self or others, poses a serious threat of damage to property affecting the security or orderly running of the institution, or is gravely disabled (manifested by extreme deterioration in personal functioning).

Id. § 549.46(a)(7). If the hearing officer determines that medication is necessary, the inmate has the right to appeal within twenty-four hours, and the staff representative must assist in preparing and submitting the appeal. See id. § 549.46(a)(8). Unless there is a “psychiatric emergency,” no medications may be administered if the inmate appeals the decision. See id. § 549.46(a)(9), (b)(1). The appeal will ordinarily be decided within twenty-four hours. See id. § 549.46(a)(9).

These regulations are substantially equivalent to the Washington procedures approved in Harper. See Harper, 494 U.S. at 215-16, 110 S.Ct. 1028. We notice two differences, however, between the BOP’s regulations and Washington’s procedures. First, the Washington policy contained a periodic review requirement. See id. at 216, 110 S.Ct. 1028. Second, the Washington policy required that the hearing be held before a three-person “special committee” comprised of a psychiatrist, a psychologist, and the Associate Superintendent of the facility. See id. at 215, 110 S.Ct. 1028. It is not clear that either of these procedures are constitutionally required. Harper simply found them to be constitutionally sufficient.

These differences do not render § 549.46 constitutionally infirm. First, a periodic review requirement is unnecessary in the context of pretrial detainees because a pretrial detainee’s status is by definition temporary — after the trial the defendant will either become a convicted inmate or a free person. Additionally, the involuntary medication order will often be part of either a determination of competency, which is limited to four months, 18 U.S.C. § 4241(d)(1), or a restoration to competency, which is limited to “an addi tional reasonable period of time,” id. § 4241(d)(2). The involuntary medication order is limited precisely because of the inmate’s status, thus diminishing the need for periodic review. Cf. Harper, 494 U.S. at 216 n. 4, 110 S.Ct. 1028 (noting that the periodic review requirement of the Washington policy was amended to require biweekly reports to the Department of Corrections medical director and a new hearing at the end of 180 days).

Second, unlike the procedures approved in Harper, BOP provides for a single hearing officer, rather than the three-person committee provided in Washington’s policy. See 28 C.F.R. § 549.46(a)(4). We do not think a multi-member committee is constitutionally compelled. Indeed, the Court in Harper focused only on the fact that a second psychiatrist — as a member of the special committee — was reviewing the medications prescribed by the inmate’s treating psychiatrist. See Harper, 494 U.S. at 222, 110 S.Ct. 1028 (“[T]he fact that the medication must first be prescribed by a psychiatrist, and then approved by a reviewing psychiatrist, ensures that the treatment in question will be ordered only if it is in the prisoner’s medical interests.... ”). BOP’s decision to provide a hearing conducted by a single non-treating psychiatrist is thus consistent with the Court’s analysis in Harper.

We now turn to Loughner’s challenges to § 549.46 generally and then to his particular challenges to his Harper III hearing.

2. Loughner’s General Challenges to 28 C.F.R. § 549.46

Loughner raises three claims. First, he argues that, as a pretrial detainee, he is entitled to a judicial, rather than an administrative, determination of his dangerousness and the need for medication. Second, he argues that the government’s burden of proof is clear and convincing evidence. Third, he argues that he is entitled to be represented at the hearing by counsel. We think that Harper largely forecloses these arguments.

a. Judicial hearing

The Court in Harper rejected the argument that an involuntary medication decision based on dangerousness grounds must be made by a judicial decision maker after a judicial hearing. Indeed, the Court concluded that “an inmate’s interests are adequately protected, and perhaps better served, by allowing the decision to medicate to be made by medical professionals rather than a judge.” Id. at 231, 110 S.Ct. 1028.

Nevertheless, citing the “rhythmically insistent pulse of Sell’s refrain,” the dissent argues that “Sell [ ] and its progeny require the district court to determine whether a pretrial detainee may be involuntarily drugged on dangerousness grounds.” Dissenting Op. at 784. But the passage that the dissent relies on, and our subsequent cases dealing with the Sell/Harper distinction, is premised on the assumption that the involuntary medication are being sought “solely for trial competence purposes.” Sell, 539 U.S. at 180, 123 S.Ct. 2174. When this is the case, Sell clearly mandates that the district court, using a higher substantive standard, make the involuntary medication determination. The dissent reads Sell to mean that the district court, applying the demanding standard of Sell, may consider whether there might be alternative means (dangerousness) of justifying the involuntary medication. Because the issue of dangerousness could be raised before the court at that point, it would be the district court that determines whether medication might be justified on Harper-type grounds. The dissent thus concludes that whenever “the government’s ultimate aim is restoration of competency” the “court must itself address the involuntary medication issue.” Dissenting Op. at 782.

The dissent reads too much into Sell. Sell tells us that “[a] court need not consider whether to allow forced medication for [trial competency purposes], if forced medication is warranted for ... the purposes set out in Harper.” Sell, 539 U.S. at 181-82, 123 S.Ct. 2174. In such a case, “the need to consider authorization on trial competence grounds will likely disappear.” Id. at 183, 123 S.Ct. 2174. When read in connection with the analysis in Harper, Sell provides that a district court may authorize involuntary medication on dangerousness grounds, using the substantive standard outlined in Harper, not that the district court must make this determination. Sell thus incorporates Harper into its structure, but nothing in Sell requires the district court to revisit the dangerousness inquiry de novo.

Loughner offers a slightly different perspective. He argues that there would be substantial added value to having judicial decision makers and a judicial hearing in the pretrial context because the administrative review is not very “probing,” the prison doctors are charged with conflicting goals, and the medical expertise of the judicial decision maker would be advanced by allowing the defense to present additional evidence at a judicial hearing.

Nothing about Loughner’s status as a pretrial detainee renders administrative review more or less “probing,” or affects the medical expertise of a potential judicial decision maker. Harper rejected these claims, and they are equally unpersuasive when applied to pretrial detainees. See id. at 233, 110 S.Ct. 1028 (“A State may conclude with good reason that a judicial hearing will not be as effective, as continuous, or as probing as administrative review using medical decisionmakers.”).

The structural conflict of interest argument was also considered and rejected in Harper. See id. at 233-34, 110 S.Ct. 1028 (noting that prior cases involving similar deprivations of liberty have approved the use of internal decision makers (citing Vitek v. Jones, 445 U.S. 480, 496, 100 S.Ct. 1254, 63 L.Ed.2d 552 (1980); Parham v. J.R., 442 U.S. 584, 613-16, 99 S.Ct. 2493, 61 L.Ed.2d 101 (1979); Wolff v. McDonnell, 418 U.S. 539, 570-71, 94 S.Ct. 2963, 41 L.Ed.2d 935 (1974))). In fact, the Court has made clear that “it is only by permitting persons connected with the institution to make these decisions that courts are able to avoid ‘unnecessary intrusion into either medical or correctional judgments.’ ” Id. at 235, 110 S.Ct. 1028 (quoting Vitek, 445 U.S. at 496, 100 S.Ct. 1254). The dissent disagrees, pointing to possible confusion in this particular case as to what FMC-Springfield’s role was in administering involuntary medication, and arguing that courts may be better situated to render objective decisions in the pretrial context. Dissenting Op. at 787-88. We maintain, however, that the decision to medicate involuntarily a pretrial detainee based on dangerousness grounds is a penological and medical decision that should be made by the medical staff. Although it is conceivable that a situation might arise in which a conflict of interest exists, “we will not assume that physicians will prescribe these drugs for reasons unrelated to the medical needs of the patients.” Harper, 494 U.S. at 222 n. 8, 110 S.Ct. 1028. Although the medical staff may have an interest in curing the patient or restoring competency, even when charged merely with determining if restoration is possible, we trust that these professionals will act within the pretrial detainee’s and prison’s best interests, within the limits of their charge. Therefore, any conflict of interest argument should be dealt with on a case-by-case basis and not deemed a bar to leaving the involuntary medication decision to the prison medical staff.

Finally, Loughner contends that a judicial determination will not be unduly burdensome because a pretrial detainee is already subject to ongoing judicial proceedings. Additional judicial proceedings, however, always have costs. Judicial determinations of medical issues occasion unnecessary intrusion into both medical and custodial judgments, see id. at 235, 110 S.Ct. 1028; see also Brief for Am. Psychiatric Ass’n & Am. Acad, of Psychiatry & the Law as Amici Curiae Supporting Affirmance (“APA Br.”) at 24, and “divert scarce prison resources, both money and the staffs time, from the care and treatment of mentally ill inmates,” Harper, 494 U.S. at 232, 110 S.Ct. 1028; see Parham, 442 U.S. at 606, 99 S.Ct. 2493; APA Br. at 24-25 (discussing increase of judicial resources after Massachusetts began requiring state courts to review involuntary medication orders). This is so regardless of whether the inmate has already been through the judicial process or is still in the pretrial phase.

The Due Process Clause requires that we measure the cost of additional procedures against the risk of error in the existing procedures and the private interest at stake. Mathews v. Eldridge, 424 U.S. 319, 335, 96 S.Ct. 893, 47 L.Ed.2d 18 (1976). Thus, the mere fact that a party can design a set of more expansive procedures does not entitle him to such process. The fact that Loughner can conceive of more process does not entitle him to it as the process that is due. Loughner has made no argument beyond his own comfort level to demonstrate the superiority of judicially directed hearings over medically directed hearings. He has offered no explanation for why there is an unacceptable risk of error “by allowing the decision to medicate to be made by medical professionals rather than a judge.” Harper, 494 U.S. at 231, 110 S.Ct. 1028.

Thus, the Due Process Clause does not require a judicial determination or a judicial hearing before a facility authorizes involuntarily medication.

b. Clear, Cogent, and Convincing Standard

Loughner next argues that because he is a pretrial detainee, the Due Process Clause requires that the determination to medicate forcibly be made by clear and convincing evidence. Harper held that a “clear, cogent, and convincing” standard “is neither required nor helpful when medical personnel are making the judgment.” Id. at 235, 110 S.Ct. 1028. Because it is the type of decision to be made and not a person’s status as a pretrial inmate that is relevant to this factor, we reject the contention that the Due Process Clause requires a heightened standard of proof.

c. Representation by Counsel

Loughner argues that a pretrial detainee is entitled to counsel at the involuntary medication hearing. This argument is largely an outgrowth of his argument for a judicial hearing. In any event, we disagree that Loughner is entitled to counsel in a BOP administrative hearing.¹³ It is not an inmate’s trial posture that governs the need for lawyers; instead, it is the nature of the judgment required. The decision to medicate involuntarily based on dangerousness grounds is a quintessential medical judgment, and in rejecting the necessity of counsel, Harper noted that “ ‘[i]t is less than crystal clear why lawyers must be available to identify possible errors in medical judgment.’ ” Id. at 236, 110 S.Ct. 1028 (quoting Walters v. Nat’l Ass’n of Radiation Survivors, 473 U.S. 305, 330, 105 S.Ct. 3180, 87 L.Ed.2d 220 (1985)). Harper then defined what would be sufficient representation: “the provision of an independent lay adviser who understands the psychiatric issues involved is sufficient protection.” Id. We agree that this is the only requirement in the pretrial context as well.

3. Loughner’s As-applied Challenges to His Harper III Hearing

We next address whether the Harper III hearing, under which Loughner is currently being forcibly medicated, complied with the procedural protections of 28 C.F.R. § 549.46. Loughner argues that even if Harper applies, his rights were violated, for four reasons: First, the decision maker failed to demonstrate that he was dangerous; second, FMC-Springfield failed to specify the course of treatment, that is, the types or dosages of drugs that may be administered to him; third, the BOP decision makers were not actually independent; and, finally, Loughner was not provided meaningful representation at the hearings.

Although no statute affirmatively grants an inmate the right to obtain judicial review of a Narper-dangerousness hearing, the court that authorized commitment in the first place pursuant to 18 U.S.C. § 4241(d) has jurisdiction over the involuntary medication order, and we have appellate jurisdiction under the collateral order doctrine. In reviewing the order, we recognize that “deference ... is owed to medical professionals who have the full-time responsibility of caring for mentally ill inmates ... and who possess, as courts do not, the requisite knowledge and expertise to determine whether the drugs should be used in an individual case.” Harper, 494 U.S. at 230 n. 12, 110 S.Ct. 1028. Giving such deference, we review Loughner’s involuntary medication order to ensure the decision is not arbitrary. See Morgan, 193 F.3d at 263 (“[S]uch a determination is subject to judicial review for arbitrariness.”).

a. Dangerousness Finding

Loughner maintains that FMC-Springfield never determined that medication was necessary to mitigate any danger that he posed to himself. In the Justification section of the Involuntary Medication Report that followed the Harper III hearing on September 15, Dr. Tomelleri cited Loughner’s deterioration after the discontinuation of antipsychotics authorized by Harper I. Loughner “expressed feelings of depression and hopelessness, complained of a radio talking to him inserting thoughts into his mind, ... engaged in yelling, crying, [and] rocking back and forth for prolonged periods of time, made statements such as that he wanted to die, [and] requested to be given an injection to be killed.” His sleep schedule became erratic, including a 50-hour period without sleep. His food intake was poor and he lost weight, and he would pace or spin in circles for hours without interruption. Since involuntary medication resumed, Loughner’s agitation has decreased, his sleep has improved, and his communication with staff is progressing, but he is still restless and paces and cries frequently. Dr. Tomelleri concluded that “[p]sychotropic medication is the treatment of choice for conditions such as Mr. Loughner is experiencing,” and rejected the alterna tives. Psychotherapy, he wrote, would “not address the fundamental problem”; minor tranquilizers are useful to reduce anxiety and agitation and were being used for that purpose; and seclusion and restraints are “merely protective temporary measures with no direct effect on the core manifestations of the mental illness.” Rejecting the argument that Loughner is no longer a danger to himself, Dr. Tomelleri stated that “[discontinuation of current medications is virtually certain to result in an exacerbation of Mr. Loughner’s illness as it did when medication was discontinued in July.”¹⁴

Loughner attempts to recharacterize his current danger to himself as being caused by his depression, which he attributes to the effects of the antipsychotic drugs because they are making him more lucid. Loughner thus alleges that the antipsychotics are not in his medical interest, but offers no medical opinion or other evidence to counter Dr. Tomelleri’s determination. By contrast, Dr. Ballenger testified before the district court that Loughner’s depression, borne of his “remorse of what happened,” is “logical” and his “self-realization [was] an indication that the medication is helping” and “a very strong indication that his psychosis is better.” We must leave such medical judgments to medical staff and professionals. See Harper, 494 U.S. at 230 n. 12, 110 S.Ct. 1028. Based on the substantial evidence in the record, we conclude that FMC-Springfield did not act arbitrarily in finding Loughner to be a danger to himself and that antipsychotic medication was in his best interest.

b. Medication Regimen

Loughner next contends that the Harper III hearing violated the Due Process Clause because no specific, future course of treatment was identified and no limitations were placed upon the types or dosages of drugs that could be administered to him. He further faults FMC-Springfield staff for modifying his medication without first seeking “ ‘due process’ authorization,” and the hearing psychiatrist for relying on the current medication regimen rather than a proposed future plan.

Loughner’s complaints may be contrary to his own medical interests. Loughner relies on three cases for the proposition that the government must specify his drug regimen in advance: Hernandez-Vasquez, 513 F.3d 908; Evans, 404 F.3d 227; and United States v. Williams, 356 F.3d 1045 (9th Cir.2004). All involved persons who were ordered involuntarily medicated, either to render them competent to stand trial, see Hernandez-Vasquez, 513 F.3d at 912; Evans, 404 F.3d at 236, or as a condition of supervised release, see Williams, 356 F.3d at 1047. In each of these cases, the defendant or probationer had not been found to be a danger to himself or others. See Hernandez-Vasquez, 513 F.3d at 915; Evans, 404 F.3d at 235 n. 3; Williams, 356 F.3d at 1057. The difference between Harper and Sell is critical here. When an inmate is involuntarily medicated because he is a danger to himself or others, he is being treated for reasons that are in his and the institution’s best interests; the concern is primarily penological and medical, and only secondarily legal. But when the government seeks to medicate an inmate involuntarily to render him competent to stand trial, the inmate is being treated because of the government’s trial interests, not the prison’s interests or the inmate’s medical in terests; the concern is primarily a legal one and only secondarily penological or medical. Hence, the Supreme Court has emphasized that resorting to a Sell hearing is appropriate only if there is no other legitimate reason for treating the inmate. See Sell, 539 U.S. at 181-82, 123 S.Ct. 2174.

Loughner’s treating psychiatrist is addressing Loughner’s serious and immediate medical needs and, accordingly, must be able to titrate his existing dosages to meet his needs, and to change medications as necessary, as other treatments become medically indicated. No one who is being treated for a serious medical condition would benefit from a court order that restricted the drugs and the dosages permissible; mental illness cannot always be treated with such specificity.¹⁵ We are not the dispensary and should let the doctors conduct their business.

The Washington policy approved in Harper required that the treatment plan be proposed by the treating psychiatrist and then approved by a reviewing psychiatrist. The purpose of this scheme, however, was not to limit the prison personnel’s future course of treatment; it was to ensure that treatment “will be ordered only if it is in the prisoner’s medical interests.” Harper, 494 U.S. at 222, 110 S.Ct. 1028. Harper did not envision a process in which medical professionals were limited to a treatment plan set out in the original hearing. Rather, the Court recognized that treatment of a mental illness is a dynamic process. See id. at 232-33, 110 S.Ct. 1028 (“Under the Policy, the hearing committee reviews on a regular basis the staffs choice of both the type and dosage of drug to be administered, and can order appropriate changes.”). Loughner’s suggestion that FMC-Springfield abused its authority by increasing the dosages and changing the types of prescribed medication ignores the realities of psychiatric medicine and overlooks the fact that BOP’s doctors have an ethical duty to do what is in the best interest of the patient. See id. at 222 n. 8, 110 S.Ct. 1028 (“[W]e will not assume that physicians will prescribe these drugs for reasons unrelated to the medical needs of the patients; indeed, the ethics of the medical profession are to the contrary.”).

Finally, even if specificity of the treatment were required, the Involuntary Medication Report from the Harper III hearing lists Loughner’s then-current medication regimen as 3 mg of risperidone, twice a day; 300 mg of buproprion XL, daily; 1 mg of benztropine, twice a day; 1 mg of clonazepam, twice a day, and 2 mg at bedtime. The report also states: “There is a documented treatment plan on patient’s chart,” and the box is checked indicating that Dr. Tomelleri considered and/or reviewed a treatment proposal and justification. Additionally, Dr. Pietz’s August 22, 2011, progress report describes Loughner’s psychiatric treatment as of that day, and we note that it is substantially the same as the treatment plan on September 15: 3 mg of risperidone, twice a day; 300 mg of buproprion XL, daily; 1 mg of benztropine, twice a day; 1 mg of lorazepam (anti-anxiety), three times a day, at bedtime, and as needed. Both his treating psychiatrist, Dr. Sarrazin, and the hearing officer, Dr. Tomelleri, have opined that Loughner requires medication. The district court heard additional testimony from Dr. Ballenger that Loughner’s medication regimen was a standard approach to his schizophrenia and other medical conditions. Loughner has offered no evidence to the contrary, and we hold that there was no due process violation relating to the medication regimen.

c. Independent Decision Makers

Loughner argues that FMC-Springfield doctors were charged with competing responsibilities and that the decision makers were not independent. Independence of the decision maker is required by 28 C.F.R. § 549.46(a)(4), however, and the hearing in this case was conducted by Dr. Tomelleri, a psychiatrist who is not currently involved in the diagnosis or treatment of Loughner. The decision to medicate Loughner was upheld by the Associate Warden, who agreed with Dr. Tomelleri’s findings, conclusions, and diagnosis. The bare fact that the involuntary medication decision was made at FMC-Springfield, by BOP-employed doctors, is insufficient to demonstrate a conflict without proof of actual bias. See Harper, 494 U.S. at 233-34, 110 S.Ct. 1028. BOP is charged with caring for those who have been committed to a detention facility; it is not a prosecuting arm of the government and has no particular interest in the continued incarceration of those inmates.

The district court found “no evidence that the FMC[-Springfield] staff is in any way an ally of the Government prosecution team,” Order on Def s Mot. to Enjoin Medication 5, and elaborated this point during the hearing:

I just don’t see any evidence whatsoever that the findings — the determination made by FMC[-Springfield] to take this action was colored in any way by considerations of how it’s going to affect the pending charges.... [The] professional staff, including the professional psychologists and psychiatrists, are calling things as they see them and they’re acting on the basis of observation and judgment and experience and training.

Hr’g on Mot. to Enjoin Tr. 50, June 29, 2011.

We are also not persuaded that FMC-Springfield is in league with the prosecution team. It was, after all, FMC-Springfield doctors who found Loughner incompetent to stand trial in the first place, a conclusion instinctively contrary to a prosecutor’s interests. Moreover, we can take notice of the fact that the same doctors involved in Loughner’s treatment have had to make these judgments in other cases, and the judgments do not always favor the prosecution. For example, in Grape, Dr. Pietz and Dr. Sarrazin opined that Grape was not competent to stand trial. 549 F.3d at 594-95. At a Harper hearing, Dr. Tomelleri found that, although Grape was a potential danger to others, he could be managed without resort to involuntary medication. See id. at 595. That finding forced the prosecution to ask for a Sell hearing, which has a much more demanding burden of proof, to medicate Grape in order to restore him to trial competency. Id. at 594-95. We can find no evidence that FMC-Springfield staff was biased or lacked independence.

The dissent argues that a conflict of interest may have existed because whereas the currently operative commitment order charges the medical staff with restoring Loughner to competency, the initial order charged FMC-Springfield only with determining whether restoration was possible. Dissenting Op. at 787-88. The dissent cites language from Loughner’s Notice of Medication Hearing and Advisement of Rights form as evidence that there may have been a “confusion of roles ... with respect to FMC-Springfield’s involuntary medication decision in this case.” Id. at 788. This form was filled out prior to the first involuntary medication decision by Loughner’s treating psychologist, Dr. Pietz, who participated in the Harper hearings, and stated that Loughner “was referred to this facility to restore competency.” Therefore, the argument proceeds, in making the initial decision to medicate involuntarily Loughner on dangerousness grounds, the medical staff may have been clouded by their interest in actually restoring him to competency.

Dr. Pietz, however, was not a key decision maker in the involuntary medication determination. 28 C.F.R. § 549.46(a)(6) requires the treating psychiatrist to attend the hearing and present data and background information demonstrating the patient’s need for antipsychotic medication; § 549.46(a)(7) vests the presiding psychiatrist, who must not be currently involved in the detainee’s treatment or diagnosis, with the authority to determine whether treatment with antipsychotic medication is necessary because of an inmate’s dangerousness; § 549.46(a)(9) vests the institution’s mental health division administrator with authority to resolve any appeal from the presiding psychiatrist’s decision. There is no evidence that these decision makers shared Dr. Pietz’s possibly mistaken understanding of the reasons for Loughner’s commitment and their concomitant statutory obligations. Therefore, the district court did not clearly err in finding that FMC-Springfield did not operate under a conflict of interest.

d. Staff Representative

Loughner argues that his appointed staff representative, John Getchell, did not adequately represent his interests at the Harper III hearing. He claims that in all three of the hearings, Getchell “failed to seek out or present any witnesses, cross-examine or challenge the prison’s witnesses, or advocate in any other meaningful way against forced medication.” Instead, Loughner contends, Getchell’s sole efforts were to relay to the administrative hearing officer Loughner’s witness request and continued objection to involuntary medication. Loughner further contends that the inadequacy of his staff representative deprived him of his substantive and procedural due process, and that he should have been afforded “[a] proper adversarial hearing, before a judge,” and with representation of counsel. The government does not dispute Loughner’s factual assertions, but argues that Getchell’s representation satisfied due process.

Due process does not require that a pretrial detainee be represented by counsel. The Supreme Court has held that providing a lay adviser who understands the psychiatric issues involved provides sufficient procedural protection. The Court has not defined further the required qualifications of the personal representative, except to hold that it need not be an attorney. See Harper, 494 U.S. at 286, 110 S.Ct. 1028. Following the procedures outlined in Harper, 28 C.F.R. § 549.46 requires that the facility provide the inmate with a staff representative for the hearing. If the inmate does not request a staff representative, or requests one with “insufficient experience or education,” FMC-Springfield “must appoint a qualified staff representative.” 28 C.F.R. § 549.46(a)(3) (emphasis added).

Although the Supreme Court has only held that it is sufficient that the representative “understand[ ] the psychiatric issues involved,” Harper, 494 U.S. at 236, 110 S.Ct. 1028, we have some concerns with the adequacy of Loughner’s representation. Loughner’s representative, Getchell, is an LCSW. We do not doubt the ability of an LCSW to understand psychological issues in general, particularly those related to counseling and psychotherapy. What is less clear is whether an LCSW has the background necessary to challenge either the diagnosis or the medical regimen prescribed by a psychiatrist.

Our concerns may stem from some confusion over the nature of Harper hearings. Although the Court characterized Washington’s policy in Harper as “an adversary hearing,” 494 U.S. at 235, 110 S.Ct. 1028, BOP’s regulations create something of a hybrid between an adversarial hearing and an inquisitorial hearing. The expectations of advocates participating in those respective hearings are quite different. The adversarial mode is party driven, as each side has the opportunity to present its best case, and the judge or hearing officer makes a decision based on the evidence the parties have mustered. Advocates take an active role, whereas the judge remains a passive participant. By contrast, in the inquisitorial model more familiar to continental systems, the judge takes a far more active role in directing the case and developing the evidence, whereas the advocate takes a passive role. See McNeil v. Wisconsin, 501 U.S. 171, 181 n. 2, 111 S.Ct. 2204, 115 L.Ed.2d 158 (1991) (“What makes a system adversarial rather than inquisitorial is not the presence of counsel ... but rather, the presence of a judge who does not (as an inquisitor does) conduct the factual and legal investigation himself, but instead decides on the basis of facts and arguments pro and con adduced by the parties.”); see also Stephan Landsman, A Brief Survey of the Development of the Adversary System, 44 Ohio St. L.J. 713, 714-15, 724 (1983); Jeffrey S. Wolfe & Lisa B. Proszek, Interaction Dynamics in Federal Administrative Decision Making: The Role of the Inquisitorial Judge and the Adversarial Lawyer, 33 Tulsa L.J. 293, 313-15 (1997). Although the adversarial model is more familiar, we have examples of inquisitorial proceedings, particularly in agencies charged with administering benefits programs, such as social security or veterans’ benefits. See Sims v. Apfel, 530 U.S. 103, 110-11, 120 S.Ct. 2080, 147 L.Ed.2d 80 (2000) (“Social Security proceedings are inquisitorial rather than adversarial.”); Nat’l Ass’n of Radiation Survivors, 473 U.S. at 309-11, 105 S.Ct. 3180 (explaining that the Veterans’ Administration benefits system is not an “adversary mode”).

The Harper hearing bears some characteristics of both systems. At first glance, the Harper hearing is decidedly adversarial because the purpose is to determine if the inmate can be medicated against his will. Unlike agency hearings to determine an applicant’s eligibility for federal largesse, the Harper hearing pits the inmate against his prison doctor in a clash over his best interests. Beyond this obvious difference, however, it is less clear that the hearing has been structured in either a plainly adversarial or plainly inquisitorial fashion. The hearing officer is not a judge but a doctor charged with confirming or rejecting the medical judgment of a colleague. That makes the hearing officer not just a neutral decision maker, but a decision maker who has been selected precisely because of his own expertise in the field. As in an inquisitorial system, the hearing officer conducts the proceeding and directs the development of the evidence. See 28 C.F.R. § 549.46(a)(4), (7).

In a Harper hearing, the government is not represented by counsel, but by the inmate’s own treating psychiatrist or psychologist who is there to testify as to why, in her judgment, the inmate’s own interests, as well as BOP’s institutional interests, require that the inmate be involuntarily medicated. The treating psychiatrist has no interest in the outcome of the hearing other than to present and defend her own diagnosis and recommendation. Importantly, she is not directing the case in the sense that we would expect from the government’s advocate in a purely adversarial proceeding. For his part, the inmate may present evidence, request his own witnesses, and ask that any witnesses be questioned. BOP’s regulations provide, somewhat ambiguously, that witnesses may be questioned either “by the staff representative or by the person conducting the hearing.” Id. § 549.46(a)(3). The staff representative also “assist[s] the inmate in preparing and submitting the appeal.” Id. § 549.46(a)(8). The acts required of the staff representative do not necessarily speak in terms of advocacy, but require that the staff representative facilitate the inmate’s presentation at the hearing and any appeal.

The role of the inmate’s staff representative changes — and perhaps dramatically — as we characterize the Harper hearing as adversarial or inquisitorial. If it is adversarial, then we would expect the staff representative to assist the inmate to present any evidence or request witnesses who would challenge his treating psychiatrist’s assessment that he is a danger to himself or others and the recommendation that the inmate be medicated against his will. Indeed, in some circumstances, we might assume that the staff representative should vigorously represent the inmate’s desire not to be medicated. On the other hand, if the Harper hearing is largely inquisitorial in nature, then the hearing officer has the primary duty to develop the evidence to his own satisfaction, and the staff representative is there to facilitate the presenting of evidence or witnesses for the inmate.

On balance, although the question is a curious one, the Harper hearing is about countermanding the desires of the inmate in an area in which he “possesses a significant liberty interest in avoiding the unwanted administration of antipsychotic drugs.” Harper, 494 U.S. at 221, 110 S.Ct. 1028. Within our traditions, and in the absence of clearer direction in the regulations, we consider the Harper hearing to be adversarial.

Based on that premise, we question whether any representative appointed by BOP who is not qualified to make medical diagnoses or prescribe medication — or, at the least, qualified by training to know what medications are typically called for to treat serious mental illnesses — can meet the inmate’s treating psychiatrist on a level playing field. We thus question whether Getchell, as Loughner’s representative, was placed in a situation where his training did not qualify him to challenge Loughner’s treating psychiatrist. In other words, in the American adversarial tradition, we wonder whether, in a contest to be decided by a hearing officer who is a psychiatrist, the hearing really pits adversaries and advocates prepared to challenge each other fairly. We do not mean to suggest that a Harper hearing requires that counsel be present, lest “[t]he role of the hearing [officer] itself ... may become more akin to that of a judge at a trial, and less attuned to the [medical] needs of the individual.” Gagnon v. Scarpelli, 411 U.S. 778, 787-88, 93 S.Ct. 1756, 36 L.Ed.2d 656 (1973). But it may suggest a more demanding role for the staff representative.

Here, Getchell’s failure to present any affirmative evidence or question any of the evidence in support of involuntary medication may indicate that his representation was unqualified or procedurally defective.¹⁶ See Morgan, 193 F.3d at 265-66 (noting that the staff representative’s lack of “meaningful participation” during the administrative hearing supported the inference that the staff representative lacked “sufficient education and experience” as required by the regulations); United States v. Humphreys, 148 F.Supp.2d 949, 953 (D.S.D.2001) (finding that the staff representative did not meet the requirements of due process because she presented no evidence; testified against the defendant, stating that she believed he had a mental illness; and may have filed a disciplinary report against the defendant when he first arrived at FMC-Rochester). Or, it may simply indicate that Getchell had nothing to say because the evidence was overwhelming that Loughner required medication and that his prescriptions were standard protocol. We cannot determine the answers to these questions from this record. If we were deciding this matter based on the Harper III hearing alone, we might well send the case back for further proceedings or a new Harper hearing.

The record in this case, however, is far more complete because the district court held an extensive hearing following Harper III. See Order Den. Stay 2, Oct. 3, 2011 (referring to “the lengthy and, at times, tedious hearing”). Thus, we think that any error that may have resulted from the staff representative’s lack of advocacy in the Harper III hearing was harmless. Three Harper hearings all reached the same conclusion: Loughner is a danger and needs to be medicated.

The Harper III hearing was followed by a district court hearing where each party had the opportunity to call witnesses. The government called Dr. Pietz, Loughner’s treating psychologist, and Dr. Ballenger, a clinical psychiatrist and independent expert. At the hearing before the district court in late September 2011, Dr. Pietz testified to her daily contact with Loughner, beginning in March 2011. She testified concerning Loughner’s behavior, her conversations with him, and his contacts with other FMC-Springfield staff. Dr. Ballenger provided a written statement and testified before the district court. Dr. Ballenger has more than forty years experience, having served as a professor at the University of Virginia Medical Center and Chairman of the Department of Psychiatry and Behavioral Sciences at the Medical University of South Carolina. He has authored or co-authored almost 400 peer-reviewed articles and 16 books, most of which deal with psychopharmaeology. Dr. Ballenger did not examine Loughner or perform a comprehensive review of his treatment records, but he had reviewed Loughner’s progress notes and had spoken to Loughner’s treating psychiatrist, Dr. Sarrazin. He provided general background on first- and second-generation antipsychotic medications and their effectiveness and side-effects. Dr. Ballenger testified regarding the drugs and dosages prescribed for Loughner, and he affirmed that the regimen was “the logical routine” and the dosages were “highly appropriate.” He confirmed that the combination of drugs Loughner’s psychiatrist had prescribed presented “no problems of using them together.”

Although the district court attempted to keep both sides “focus[ed] on the issue of the day” — i.e., the extension of commitment under 18 U.S.C. § 4241(d)(2) — the district court also addressed the adequacy of the Harper III hearing. Thus, at the hearing, Loughner had the opportunity to challenge the assessments of his doctors, and to present evidence that the dangerousness finding at his Harper hearings was arbitrary. Loughner’s counsel cross-examined both Dr. Pietz and Dr. Ballenger. His counsel called no witnesses, but produced graphs and charts compiled from Loughner’s own FMC-Springfield medical records. Ultimately, the government’s presentation was nearly unchallenged by Loughner’s counsel. Indeed, over the course of months, and numerous hearings before the district court, Loughner has never presented any witnesses or other evidence that calls into question his diagnosis or treatment. The evidence before the district court thus fully supported the judgment reached at the Harper hearings.

Additionally, in making the finding that there was “a substantial probability that within a reasonable period of time ... Mr. Loughner can be restored to competency,” see 18 U.S.C. § 4241(d)(2), the district court relied on Loughner’s “ongoing treatment” at FMC-Springfield. Because his “ongoing treatment” necessarily encompassed the involuntary medication of Loughner, a current, valid involuntary medication order must exist. Thus, Loughner effectively had two chances to attack the existing Harper order during the hearing regarding the extension of his commitment: by either attacking the Harper order directly or as a challenge to the § 4241 determination. But Loughner called no witnesses, introduced no new evidence, and did not allege that the doctors chose a course that was medically inappropriate. Any deficiency in Getchell’s representation in Loughner’s case was cured in the district court’s subsequent hearing.

‡ ‡ ‡

We conclude that Loughner was provided with the substance and procedure demanded by the Due Process Clause before the government involuntarily medicated him. It is clear that Loughner has a severe mental illness, that he represents a danger to himself or others, and that the prescribed medication is appropriate and in his medical interest. There was no arbitrariness in the district court’s order denying the motion to enjoin Loughner’s emergency treatment. He may be involuntarily medicated.

IV. COMMITMENT TO RESTORE COMPETENCY

We next turn to Loughner’s appeal of the district court’s extension of his commitment. This is a separate inquiry and, although the issues are related, we must keep the issues distinct. The dissent, however, argues that the involuntary medication and commitment decisions are one and the same. See Dissenting Op. at 784-85. Because “the court ... must decide whether Loughner is to be medically treated so as to be restored to competency” and because that decision “depends on the availability of involuntary medication,” the dissent argues that the district court may not rely on a previous involuntary medication order, but instead must make an independent decision as to whether the medication is justified and unlikely to infringe on Loughner’s fair trial rights. Id. at 781-82. But these determinations must be kept separate. 18 U.S.C. § 4241(d)(2) requires a court to decide whether “there is a substantial probability that ... [the detainee] will attain the capacity to permit the proceedings to go forward.” Although the court will necessarily have to consider the preexisting treatment that will lead to such attainment, the basis for that treatment, when it is involuntary medication, is 28 C.F.R. § 549.46. This is a completely separate authorization, and one that the Supreme Court has indicated may be made in an administrative hearing. We therefore address whether, given the currently operative involuntary medication order, the district court properly extended Loughner’s commitment pursuant to § 4241(d)(2).

Under 18 U.S.C. § 4241(d), if a court finds that a defendant’s mental disease renders him “mentally incompetent to the extent that he is unable to understand the nature and consequences of the proceedings against him or to assist properly in his defense,” the court shall commit the defendant for up to four months to determine if there is a “substantial probability” that he will be restored to competency. 18 U.S.C. § 4241(d)(1). After such time, the court shall commit the defendant “for an additional reasonable period of time until” he is fit to proceed to trial, “if the court finds that there is a substantial probability that within such additional period of time he will attain the capacity to permit the proceedings to go forward.” Id. § 4241(d)(2); see also Jackson v. Indiana, 406 U.S. 715, 738, 92 S.Ct. 1845, 32 L.Ed.2d 435 (1972).

In challenging the extension of his commitment, Loughner raises three claims. First, he contends that the district court’s order extending his commitment is flawed because the court failed to demand a particularized course of treatment from FMC-Springfield. Second, he argues that the district court did not consider whether the antipsychotic medications would render his trial unfair. Third, he maintains that the district court clearly erred in finding that there is a “substantial probability” that Loughner will regain competency. We will consider each in turn.¹⁷

A. Particularized Course of Treatment

Loughner argues that the district court failed to consider the medical appropriateness of his treatment regimen and, without considering that regimen, could not assess the likelihood of Loughner being restored to competency.

We think Loughner has failed to distinguish between the reasons for which he may be medicated pursuant to Harper— reasons that predominantly have to do with the prison’s and his own medical interests — and the reasons for which he may be medicated pursuant to Sell — which involve the government’s interests. Loughner is being medicated for his serious mental illness irrespective of whether he can concomitantly be restored to competency in order to stand trial. The purpose of the district court’s hearing was to determine whether, in light of his existing treatment, there is a “substantial probability that within [the] additional period of time he will attain the capacity to permit the proceedings to go forward.” 18 U.S.C. § 4241(d)(2). If his current regimen is sufficient to determine that there is a substantial probability that he can be rendered competent, then he can be “hospitalize[d] ... in a suitable facility.” Id. § 4241(d). If, however, the treatment for his dangerousness will not concomitantly render him trial-competent, then additional medication could be forced upon him only if it is in the government’s (rather than his own) interests, and in such case the government would have to proceed under Sell. As the Court explained in Sell, “[a] court need not consider whether to allow forced medication for [trial competency purposes], if forced medication is warranted for a different purpose.... If a court authorizes medication on these alternative grounds, the need to consider authorization on trial competence grounds will likely disappear.” 539 U.S. at 181, 183,123 S.Ct. 2174.

We agree with Loughner that the existing involuntary medication decision is important to the overall outcome of the § 4241(d)(2) proceeding because it “likely affect[s] both the scope and term of a § 4241(d)(2) order.” United States v. Magassouba, 544 F.3d 387, 418 n. 27 (2d Cir.2008). Section 4241(d), however, is a commitment statute, not an involuntary medication statute, and a § 4241(d)(2) extension of commitment for purposes of competency restoration does not alter the legitimacy of the decision to medicate involuntarily Loughner under Harper. The court must therefore consider only whether his ongoing treatment is likely to restore competency, not whether it is medically appropriate. The medical appropriateness of Loughner’s treatment was addressed in his Harper hearing, and we have approved that treatment. See supra Part III.

In any event, the district court heard “what medications the defendant is receiving, what dosages of those medications he is receiving, and when during the day he is receiving those dosages.” Order Den. Stay 4-5. Although the district court assumed that the “present medication regimen will continue with only minor modifications,” id. at 5, the district court heard testimony that Loughner’s medication regimen has changed in the months that he has been committed to FMC-Springfield, and his treating psychologist, Dr. Pietz, testified that his medication might continue to change. Dr. Ballenger testified that the medication currently administered to Loughner was “highly appropriate” but that if Loughner does not fully respond to the medication, it would be “a very appropriate strategy” to increase the dosages, even doubling some. But the administration of antipsychotic drugs is a fluid process and must be adjusted depending on how the patient reacts and why, if any, side effects are experienced. See APA Br. at 26 (“[T]he choice whether and how to medicate an inmate is not a one-time decision; it involves a process of monitoring and, for many patients, adjustments in medication and dosage.”); see also Indiana v. Edwards, 554 U.S. 164, 176, 128 S.Ct. 2379, 171 L.Ed.2d 345 (2008) (“Mental illness itself is not a unitary concept. It varies in degree. It can vary over time. It interferes with an individual’s functioning at different times in different ways.”). Requiring FMC-Springfield to submit with particularity the exact course of treatment over several months is impractical and unnecessary, and would ignore the concerns expressed in Harper that medical decisions should not be made by judges. See Harper, 494 U.S. at 232, 110 S.Ct. 1028 (“ ‘The mode and procedure of medical diagnostic procedures is not the business of judges(quoting Parham, 442 U.S. at 607, 99 S.Ct. 2493)); id. at 231 n. 12, 110 S.Ct. 1028 (stating that deference should be given to medical professionals in making medication decisions because courts do not have the necessary knowledge or expertise).¹⁸

The district court found that Loughner was being lawfully medicated pursuant to Harper and that there was a substantial probability that his existing treatment will restore him to competency to stand trial. In the process, the court considered Loughner’s existing regimen but did not undertake to micromanage his treatment or otherwise limit his course of treatment. See Harper, 494 U.S. at 231 n. 12, 110 S.Ct. 1028; Hernandez-Vasquez, 513 F.3d at 916-17. The Due Process Clause does not demand more.

B. Side Effects and Fair Trial Rights

Loughner argues that when forced medication is the means employed by BOP to seek restoration of competency, the district court must engage in a predictive analysis of whether side effects are substantially unlikely to render a trial unfair before the defendant can be committed under § 4241(d)(2). Specifically, Loughner argues that the district court must predict whether the antipsychotic medication is substantially unlikely to alter his demeanor in a manner that will prejudice his reactions and presentation in the courtroom, and render him unable or unwilling to assist counsel. Loughner’s concerns are well-taken, but premature. As the district court recognized, Loughner will have a full and fair opportunity to raise his concerns before he goes to trial. See Order on Sell Hr’g 8. To demand that the district court answer such questions at this juncture blurs the distinction between a defendant who is being medicated under Harper and one the government seeks to medicate under Sell.

Before a defendant can be committed for evaluation of his competence, the district court must find that the defendant “is unable to understand the nature and consequences of the proceedings against him or to assist properly in his defense.” 18 U.S.C. § 4241(d). The premise for granting the government’s motion for a competency examination of Loughner at FMC-Springfield in March 2011 was “reasonable cause to believe” that he was not competent to understand trial procedures or to assist in his defense. Id. § 4241(a). That belief was confirmed shortly after Loughner was committed. Before granting an extension of commitment for the purpose of restoration, the district court must find that there is a substantial probability that the pretrial detainee “will attain the capacity to permit the proceedings to go forward.” Id. § 4241(d)(2). Once these findings are made, the court must then commit the defendant for a reasonable period of time until trial may proceed. Id. The statute itself therefore contemplates that the “capacity” that the district court is required to predict is the ability to understand the nature and consequences of the proceedings and to assist in his defense— in other words, competency. See United States v. Marks, 530 F.3d 799, 814 (9th Cir.2008) (“The substantive standard for determining competence to stand trial is whether the defendant had sufficient present ability to consult with his lawyer with a reasonable degree of rational understanding, and a rational as well as factual understanding of the proceedings against him.” (internal quotation marks omitted)); see also Edwards, 554 U.S. at 174, 128 S.Ct. 2379 (explaining that the Supreme Court’s “mental competency” cases have defined “competency” in terms of “the capacity to understand the nature and object of the proceedings against him, to consult with counsel, and to assist in preparing his defense”) (emphasis omitted) (quoting Drope v. Missouri, 420 U.S. 162, 171, 95 S.Ct. 896, 43 L.Ed.2d 103 (1975)); Order Extending Restoration Commitment 2 n. 1 (finding that competency and capacity are equivalent).

Sell requires, among other things, that the government demonstrate not only that involuntary medication is “likely to render the defendant competent to stand trial,” but that “administration of the drugs is substantially unlikely to have side effects that will interfere significantly ■with the defendant’s ability to assist counsel in conducting a trial defense.” Sell, 539 U.S. at 181, 123 S.Ct. 2174; see also id. at 185, 123 S.Ct. 2174 (“Whether a particular drug will tend to sedate a defendant, interfere with communication with counsel, prevent rapid reaction to trial developments, or diminish the ability to express emotions are matters important in determining the permissibility of medication to restore competence.... ”). That predictive judgment is required where the government seeks to medicate the defendant for no reason other than to render him competent. As we have pointed out, Loughner is being medicated involuntarily because he is a danger to himself or others, irrespective of whether the medications may cause side effects that interfere with his ability to assist counsel in his defense. A district court’s judgement on side effects is both premature and irrelevant at this stage. See Order Den. Stay 3 (“It was obviously premature at this stage of the competency restoration process for the Court to determine whether there are side effects of the defendant’s medication that will prevent the Court from making a finding of competency in the future.”).

Because Loughner remains under medical treatment for his mental illness, the district court properly focused on whether his treatment might also restore him to competency. The district court acknowledged that Loughner’s concerns “will be fully addressed if there is a future competency hearing.” Order on Sell Hr’g 8. We agree that such concerns are important and that Loughner should have an opportunity to raise these issues. We also agree that the district court need not address Loughner’s concerns before deciding to extend his commitment to determine whether he can be restored to competency.

C. Substantial Probability of Restoration of Competency

Loughner contends that the district court applied .the wrong legal standard in granting the extension of commitment, arguing that the “substantial probability” of restoration must be proven by clear and convincing evidence. First, we agree with the district court that a second layer of proof is not required and that the statute itself provides the requisite burden of proof — the government must prove there is a “substantial probability” that Loughner will regain competency. See 18 U.S.C. § 4241(d)(2)(A).

Next, in defining that standard, the district court noted that “a ‘substantial’ probability is any probability worth taking seriously.” Order Extending Restoration Commitment 3. To demonstrate this proposition, the court used an analogy: “For example, a 40 percent chance of rain is enough of a reason to leave the house with a raincoat, or cancel plans to spend a day outside; it wouldn’t be unreasonable to label that chance ‘a substantial probability,’ even if rain is not substantially probable.” Id. The district court then looked to Ninth Circuit precedent, finding that “ ‘courts have generally construed § 4241(d)(2) to allow extensions for a reasonable period of time only when the individual is likely to attain competency within a reasonable time.’ ” Id. at 4 (emphasis added) (quoting Rivera-Guerrero, 426 F.3d at 1143) (some internal quotation marks omitted). The district court’s determination that “substantial probability” means “likely” (and not necessarily “more likely than not”) was based on both a fair reading of the statute and the guidance of our precedent and, therefore, we agree.

Loughner further challenges the district court’s finding that there was a “substantial probability” that Loughner can be restored to competency as clear error. He raises three objections to the district court’s § 4241(d)(2) finding: (1) that his past improvement does not support an inference that his condition will continue to improve to the point of competency, (2) that expert opinion regarding the amount of time required for restoration was unsupported by any specific data and impermissibly relied on generalities, and (3) that the district court improperly relied on Dr. Ballenger’s testimony because it equated functional competency with trial competency. After reviewing the evidence, we are not “left with the definite and firm conviction that a mistake has been committed.” Ruiz-Gaxiola, 623 F.3d at 693 (citations omitted) (internal quotation marks omitted).

1. Past Improvement

Loughner argues that because a response to medication will eventually plateau, some additional indication beyond past improvement is required to establish a probability that his condition will continue to improve to the point of competency. In concluding that Loughner was likely to continue improving, however, the district court did not rely solely on Loughner’s past improvement. The court based its finding on Loughner’s positive response to the antipsychotic drugs, including the lack of significant side effects; Dr. Pietz’s testimony regarding Loughner’s progress and potential for further progress; the experience of Dr. Ballenger, corroborating the “optimistic viewpoint and prognosis” of Dr. Pietz; and his own observations of Loughner’s improvement. Regardless, past experience is often the best predication of future performance, and the district court did not clearly err in basing its determination of the likelihood of competency restoration on readily available evidence of Loughner’s reaction to antipsychotic medication already administered, and the views of the medical experts who testified.

2. Time Required for Restoration to Competency

Loughner next disputes the district court’s finding that restoration would be accomplished in four months, and the basis for Dr. Pietz’s opinion that Loughner could be restored to competency within eight months.

In her progress report on September 7, 2011, Dr. Pietz opined that Loughner remained incompetent to stand trial. She requested an extension of his commitment because she believed that Loughner would improve and reach competency to stand trial. Dr. Pietz could not predict how much additional time was required, but she noted that “[historically, most defendants reach competency within 8 months of their commitment,” and recommended that Loughner’s commitment be extended for four months. At the extension hearing, Dr. Pietz clarified that “the eight months goes to when we start to medicate [him].” In coming to the eight-month figure, Dr. Pietz relied on her experience restoring defendants to competency over twenty-one years, her colleagues’ experience, a book, and several articles that were presented to the district court. She did not have, however, any formal data from which she based her figure of eight months. Dr. Pietz further explained that she recommended an extension of commitment for four months because, based on her understanding of the statute and her experience, extensions are granted in four-month increments, with the possibility of a second extension if necessary. See 18 U.S.C. § 4241(d). Based on the testimony that he heard from Dr. Pietz, a review of the records in this case, and his own experience, Dr. Ballenger confirmed that it is “highly likely” that Loughner will get clinically better in “two to six, eight more months.”

The district court found that Dr. Pietz is credible, experienced, and qualified to make the judgments required of her during the commitment hearing. The court further credited Dr. Pietz’s day-to-day personal contact with Loughner, as well as her “barometer on whether he’s made progress [and] whether he’ll continue to make marked progress.” Status Hr’g Tr. 275. Additionally, Dr. Pietz’s opinion was supported by the testimony of Dr. Ballenger, an “experienced and well-credentialed psychiatrist.”

The district court did not rely exclusively on the experts. At the hearing, the district judge found that “measurable progress toward restoration has been made,” id., and offered his own observation of Loughner’s progress:

I watched Mr. Loughner today as I have in the other proceedings. His demean- or, while all the characterizations are correct about flat affect and all, has been distinctly different than in other proceedings.... The smirk, what we referred to as affect, is gone. He’s appeared to pay attention to the proceedings today. In earlier proceedings, the court notes that he wasn’t particularly paying attention. He was looking down, looking away, didn’t seem connected at all. Today, in my lay view, he does appear to be more connected to the proceedings, appears to be paying attention to what’s going on.

Id. at -276-77. After admitting that he is “not a physician,” the district court judge concluded that “everything I observe about [Loughner] seems to connect with the expert testimony that I’ve heard; that there is reason to be optimistic, that he will recover and be able to assist his lawyers in defending him against this case.” Id. at 277.

Next, the district court determined the appropriate length of the commitment extension. The court considered Dr. Pietz’s request for an additional eight months, as modified from hér original request for four months, based on her prior understanding of the statute and case law. Recognizing that “[fit’s for me to determine what is a reasonable period of time,” the district judge explained that he could not “at this point [predict] that it would be four months or eight months.” Id. at 278. The court also noted that it was established that if Dr. Pietz or the physicians at FMC-Springfield determined that Loughner was restored to competency before the end of the four-month extension, the court would be notified. Thus, following another district court decision, the district court set a four-month period, with the possibility of granting another extension if necessary. See United States v. Rodriguez-Lopez, No. CR 08-2447, 2010 WL 4339282, at *8 (D.N.M. Sept. 22, 2010) (“Section 4241 provides insight into the measure of a reasonable ‘additional period of time’ by establishing that an initial reasonable period is ‘not to exceed four months.’ The statute appears to contemplate one four-month term followed by another four-month term.” (citation omitted)).

The district court based its § 4241(d)(2) determination on the credible testimony of both Dr. Pietz and Dr. Ballenger; a reading of all the evidence in the record, including contrary evidence presented by Loughner; and the district judge’s own observations. Loughner did not offer any evidence that he could not be restored to competency within four months. We find that the district court considered proper evidence before it and did not clearly err in determining that there was a substantial probability that Loughner would be restored to competency within four months.

3. Trial Competency and Clinical Competency

Loughner finally argues that the district court erred in accepting Dr. Ballenger’s testimony as a proxy for competency restoration. See Riggins, 504 U.S. at 141, 112 S.Ct. 1810 (Kennedy, J., concurring) (“The avowed purpose of the [involuntary] medication is not functional competence, but competence to stand trial.”). In the oral ruling on September 28, the district court acknowledged that clinical competence

is a proxy, that is a parallel of what’s going on here. Restoration in the case of someone in a clinical setting, for all intents and purposes, is the same goal that we have in this case, which is to get somebody functioning again as a human being who understands, appreciates, and assists in the context of the criminal case with the defense of his case.

Status Hr’g Tr. 276.

Although restoration in the clinical setting may not be “the same goal” as restoration for trial competency, Dr. Ballenger’s testimony was certainly relevant for determining the likelihood of restoration, generally, of signs of an improvement in mental disease (and thus whether Loughner’s condition has improved thus far), and the likelihood of restoration given Loughner’s current treatment regimen. Thus, the district court did not clearly err in relying on Dr. Ballenger’s testimony to support a finding that there was a substantial probability that Loughner would attain the capacity to permit the proceedings to go forward.

íJí >}c :-í i|i Hí ❖

The district court did not commit legal error in its commitment rulings, and its finding that there is a substantial probability that Loughner will be restored to competency in the foreseeable future is supported by the evidence and not clearly erroneous. Loughner may be committed pursuant to the district court’s order and subject to its supervision.

V. CONCLUSION

The judgment in No. 11-10504 is AFFIRMED. Because the Harper III hearing supercedes the prior Harper hearings and the emergency medication order, appeals No. 11-10339 and No. 11-10432 are DISMISSED as moot.

Footnotes

*

Appeal No. 11-10339 was argued and submitted on August 30, 2011. Appeal No. 11-10504 was argued and submitted on November 1, 2011. Appeal No. 11-10432 was submitted, without argument, on February 27, 2012.

1

. The regulation was amended effective August 12, 2011. See 76 Fed.Reg. 40229, 2011 WL 2648228 (Aug. 12, 2011). The former § 549.43 is now contained in § 549.46.

2

. Riggins v. Nevada, 504 U.S. 127, 112 S.Ct. 1810, 118 L.Ed.2d 479 (1992).

3

. Sell v. United States, 539 U.S. 166, 123 S.Ct. 2174, 156 L.Ed.2d 197 (2003).

4

. The current regulation is located at 28 C.F.R. § 549.46(b)(1).

5

. Dr. Pietz explained at the September 28th hearing that she initially limited her extension request to four months because, in her experience, judges ordinarily granted extensions in four-month increments.

6

. On February 8, 2012, the district court extended Loughner’s commitment for the purpose of competency restoration to June 7, 2012. Dr. Pietz reported to the district court that Loughner remains incompetent to stand trial but that he has made substantial progress. The government and Loughner filed a Joint Notice in which they indicated that they had no further evidence to present.

The extension of the commitment for competency restoration does not moot the issues in this appeal.

7

. In No. 11-10339, Loughner appeals from the district court's denial of his motion challenging the June 14 involuntary medication decision, Harper I. Because Harper I is no longer operative, but the bulk of the legal arguments in that appeal apply also to the Harper III appeal, we have consolidated the cases and will consider the briefs, records, and arguments from both appeals as applied to the September 15 Harper III hearing — the currently operative involuntary medication order. No. 11-10339 is therefore dismissed as moot.

In No. 11-10432, Loughner appeals from the district court's denial of a prompt post-deprivation hearing after the emergency medication decision of July 18, 2011. Because that involuntary medication order is no longer operative, and because there is no relief that can be granted by this court, that appeal is dismissed as moot.

8

. We note that although Loughner cites 28 U.S.C. § 1292 as an alternative basis for jurisdiction, and initially filed a motion to enjoin in the district court, the parties appear to have addressed the issues as though this was a direct appeal from the involuntary medication order and not an appeal from a denial of a motion for an injunction. See 28 U.S.C. § 1292(a)(1) (providing appellate jurisdiction for denial of an injunction). Because direct appellate review through the collateral order doctrine does not add another layer of review, and because this result is urged by Loughner and acceded to by the government, we have proceeded in that manner. Cf. Winter v. Natural Res. Defense Council, Inc., 555 U.S. 7, 32, 129 S.Ct. 365, 172 L.Ed.2d 249 (2008) (reviewing an injunction for abuse of discretion). We also note that it is not necessary for a defendant to go the route of an injunction to have the administrative Harper order reviewed in the district court. The district court’s authority to review pretrial orders naturally extends to a review of pretrial medication orders.

9

. The dissent argues that we have addressed "the questions before us in the wrong order" because the "commitment decision is the currently operative one.” Dissenting Op. at 781 (emphasis omitted). Contrary to this claim, however, determining whether the involuntary medication order is currently operative— i.e., is not substantively or procedurally deficient — is a necessary predicate to determining whether Loughner’s commitment for the purpose of competency restoration is justified. This is so because, as we explain, if Loughner must be involuntarily medicated because he is a danger to himself or others, then he will be medicated irrespective of whether that treatment will restore him to competency. See Sell, 539 U.S. at 181-82, 123 S.Ct. 2174. We therefore first address whether Loughner’s current involuntary medication order comports with constitutional requirements, and then address the extension of his commitment for the purposes of competency restoration.

10

. We note that some of the Court's concerns in Harper have been lessened to some extent by significant pharmacological advances. The drugs at issue in Harper — Trialafon, Haldol, Prolixin, Taractan, Loxitane, Mellaril, and Navane, 494 U.S. at 214 n. 1, 110 S.Ct. 1028 — were first-generation antipsychotics. As Dr. Ballenger explained at Loughner’s commitment hearing, the "almost miraculous promise of second-generation [medications] is people still get well, but with markedly less" side effects: the frequency of tardive dyskinesia is "[a] fifth or one-tenth of what it was before”; neuroleptic malignant syndrome is "vanishingly rare”; extrapyramidal effects (Parkinson-like disorders) that had an inddence rate of 75% with Haldol occur "very rarely,” at the same level as with a placebo; and “akathisia is also markedly less frequent.” See Grape, 549 F.3d at 596 (citing testimony from a FMC-Springfield psychiatrist that "[t]hese side effects, especially neuroleptic malignant syndrome, EPS or stiffness, and tardive dyskinesia, which could be permanent, are less common in second-generation antipsychotics than in first-generation medicines such as haloperidol”); United States v. Evans, 404 F.3d 227, 233-34 (4th Cir.2005) (discussing the involuntary medication report’s conclusion that “second-generation, or atypical antipsychotic medications” have a reduced risk of side effects).

11

. Furthermore, in Sett, the Court observed that FMC-Springfield and the magistrate judge held dangerousness hearings “applying standards roughly comparable to those set forth here and in Harper.” Sett, 539 U.S. at 183, 123 S.Ct. 2174. The magistrate judge approved Sell's medication on dangerousness grounds. Although the district court found that conclusion clearly erroneous, the court of appeals agreed, and the government did not appeal the finding, the Supreme Court noted that "[i]f anything, the record before us ... suggests the contrary,” before proceeding on the "hypothetical assumption” that Sell was not dangerous. Id. at 184-85, 123 S.Ct. 2174. If the Court had any remaining doubts about the nature of the hearings, it had ample opportunity to renew its disclaimer in Riggins or otherwise question the standards used by FMC-Springfield and the magistrate judge.

12

. We note that in Weston, 206 F.3d 9, a preSell decision, the panel questioned whether, in light of Riggins, Harper applied to pretrial detainees. Compare id. at 14 (Henderson, J., concurring) ("[T]he applicable standards for reviewing an institution's medical/safety determination appear to me, at least, to be the same for a detainee as for a convicted inmate.”), with id. at 17 (Rogers, J., concurring) ("The Supreme Court may ultimately articulate a standard for pretrial detainees that is different from the one applied in Harper to a prison inmate...."). So far as we can determine, the D.C. Circuit has not revisited the question after Sell.

13

. We have some additional concerns with how, short of having legal counsel, a detainee’s interests are represented at the dangerousness hearing. These are addressed infra at Part III.B.3.d.

14

. Dr. Tomelleri noted that, during the hearing, Loughner complained of "drowsiness” and said that his treating psychiatrist would modify his medications to address this side effect.

15

. We have recognized that such specificity is appropriate when an inmate is not a danger to himself or to others and is being medicated pursuant to Sell. See Hernandez-Vasquez, 513 F.3d at 916-17; Rivera-Guerrero, 426 F.3d at 1140, 1142. Even as we have expressed concern "not to grant physicians unlimited discretion in their efforts to restore a defendant to competency for trial,” we have also stated that we will not “micromanage the decisions of medical professionals” and must "give physicians a reasonable degree of flexibility.” Hernandez-Vasquez, 513 F.3d at 916-17. Noting "that instances in which an order for involuntary medication would be appropriate under Sell ‘may be rare,' ” we advised that it may be better "if the facts warrant, to find another legal basis for involuntary medication." Id. at 916 (quoting Sell, 539 U.S. at 180, 123 S.Ct. 2174).

16

. The government points out that one of Loughner’s attorneys, Anne Chapman, acted as a witness by submitting a written statement raising factual and legal arguments against involuntary medication. A written statement, however, may not necessarily cure a procedural defect because it does not afford the opportunity to respond to evidence or arguments put forward at the hearing.

17

. We review the district court’s legal conclusions de novo and its factual findings for clear error. See Ruiz-Gaxiola, 623 F.3d at 693. We review a district court’s competency determination for clear error. Friedman, 366 F.3d at 980; United States v. Gastelum—Almeida, 298 F.3d 1167, 1171 (9th Cir.2002). "A trial court’s factual finding is clearly erroneous when, although there is evidence to support it, the reviewing court on the entire evidence is left with the definite and firm conviction that a mistake has been committed.” Ruiz-Gaxiola, 623 F.3d at 693 (internal quotation marks omitted).

18

. The district court noted that there was no "evidence that the FMC[-Springfield] staff is medicating the defendant under Harper just to avoid a more stringent Sell hearing.... The FMC[-Springfield] staff has no obligation to restore the defendant to competency, and indeed, the staff is free to report to the Court that the defendant cannot be restored or has not been restored within the time allowed.” Order on Sell Hr'g 6 n. 3, Oct. 27, 2011.